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Transforming growth factor β (TGFβ) is an immunosuppressive cytokine with multiple functions 
in the immune system, including regulation of cytotoxic T lymphocytes. This thesis will examine 
how TGFβ, and the downstream signaling molecule Smad4, alter the CD8 T cell response to 
infection with different strains of influenza A virus (IAV). Chapter III shows how TGFβ and 
Smad4 regulate the phenotype, localization and function of antigen-specific CD8 T cells in the 
lungs. Our data reveal a previously unappreciated role of Smad4 in regulating effector and 
memory CD8 T cell differentiation independently of TGFβRII. Specifically we find that Smad4 
promotes terminal differentiation of KLRG1+ T effector (TEFF) cells, a subset that is inhibited by 
TGFβ. Smad4 and TGFβ also play reciprocal roles in regulation of CD103+ tissue resident 
memory T (TRM) cells and CD62L+ central memory T (TCM) cells. Altered expression of multiple 
homing receptors changes the distribution of antigen-specific CD8 T cells in vivo, and therefore 
impacts viral clearance during primary viral infection and heterosubtypic immunity. Chapter IV 
explores the mechanism by which Smad4 regulates the CD8 T cell response, by examining the 
global transcription profile, cellular metabolism and signaling pathways of mutant and wild type 
CTLs. Our data suggests that Smad4 is activated by a novel pathway to promote terminal 
differentiation of effector T cells possibly through enhancing IL-12 signaling and T-bet 
expression, and inhibiting OXPHOS activity. Also, by enhancing T-bet and Eomesodermin, 
Smad4 may act as a suppressor of CD103 and later promotes re-expression of CD62L. This 
novel pathway of Smad4 ligand is counter-regulated by TGFβ, possibly by competing for Smad4 
with phosphorylated Smad2/3. Our study sheds new light on the signals that regulate the 
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differentiation and distribution of virus-specific CD8 T cells during IAV infection, which can be 
utilized to optimize cell-mediated immunity during the design of IAV vaccine.  
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1. Influenza virus and human disease 
Infection with Influenza A virus (IAV) is a leading cause of respiratory disease-associated 
morbidity and mortality. Worldwide, these viruses result in about 3 to 5 million cases of severe 
illness, and about 250,000 to 500,000 deaths annually. In the United States, there are around 
300,000 hospitalizations with more than 40,000 deaths each year (1;2). In addition to the 
seasonal epidemics, global pandemics occur when new strains of IAVs cause widespread 
infection and high mortality rates as people have little pre-existing immunity (3;4). Elderly people 
are at particularly high risk for complications during IAV epidemics, with nearly 60 percent 
hospitalizations being among people 65 years or older (5). Other vulnerable groups include 
young children, pregnant women and people with chronic disease or a weakened immune 
system (6). The symptoms of seasonal influenza infection are characterized by high fever, 
cough, headache, muscle and joint pain, sore throat and runny nose. Most adults recover from 
the infection within 1-2 weeks. The mortality is usually driven by two different mechanisms (7;8). 
Some IAVs are highly pathogenic and induce the release of large quantities of inflammatory 
cytokines in the lungs, leading to local vascular leakage and alveoli damage (9). Other less 
pathogenic viruses can induce a transient period of immune suppression that facilitates 
secondary bacterial infections in the respiratory tract (10). 
IAVs belong to the Orthomyxoviridae family of enveloped viruses with a segmented genome 
comprised of single-strand, negative-sense RNA. The 8 RNA segments encode 11 proteins, 
including hemagglutinin (HA), neuraminidase (NA), and matrix protein M2, which are embedded 
in the viral envelop (11). Inside the envelope are the matrix protein M1, and complexes of 
nucleoprotein (NP) and RNA polymerase proteins. The subunits are polymerase acidic protein 
(PA), polymerase basic proteins 1 and 2 (PB1 and PB2), and PB1-F2 which is encoded by an 
alternate reading frame within the PB1 gene. There are also two non-structural proteins (NS1 
and NS2) (11;12). HA enables the binding of the viral particles to sialic-acid groups on the 
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surface of host cells and subsequent endocytosis. The low pH environment inside the 
endosome induces a conformational change which mediates the fusion of the viral HA and 
opens a pore in the endosomal membrane. The M2 protein is part of a pH activated ion channel 
which enables the internal acidification of the influenza virion and the release of viral RNPs into 
the cytoplasm (13;14). Importantly, HA is synthesized as a precursor molecule which must be 
cleaved by extracellular proteases that are expressed in specialized cells in the human 
respiratory tract (15). Viral RNP is then transported into the nucleus where the negative-sense 
viral RNA is used as a template to transcribe messenger RNA (mRNA) for the production of viral 
proteins, and complementary RNA (cRNA) which is the genome of new viral RNAs. The nascent 
viral proteins and RNAs are then packaged into particles and budded from host cells (16). NA is 
essential for the release of newly synthesized virions from cell surface by cleaving sialic acid 
groups that are bound to HA (17). 
2. Protection by the adaptive immune response 
A. Humoral immunity 
Most licensed influenza vaccines confer protection against clinical disease by targeting the 
humoral immune response (12;18). Antibodies that are specific for HA provide immediate 
protection at mucosal sites by neutralizing infectivity, whereas NA-specific antibodies restrict 
viral dissemination by preventing the release of new virions. The viral coat proteins undergo 
constant genetic mutation to escape the host immune response. High mutation rates are 
characteristic of RNA viruses and cause antigen drift. In addition, re-assortment of the 
segmented genome can occur during co-infection of two different strains and produce a re-
assorted strain which is referred to as an antigenic shift (12). Antibodies to the coat proteins are 
used to identify different serotypes. Currently, 18 HA (H1-H18), and 11 NA serotypes (N1-N11) 
have been recorded (19). Currently most antibody-based vaccines are unable to provide 
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protection against multiple serotypes of IAV, and therefore require constant reformulation to 
target new strains, leading to huge economic burden as well as substantial failure rates (1).  
B. Cellular immunity  
CD8 T cells play an active role in viral clearance, by directly eliminating infected epithelial cells 
(20). Importantly, some CD8 T cells are specific for epitopes derived from internal viral proteins 
that are highly conserved between different strains (21), and can therefore provide immunity 
between serologically distinct strains known as heterosubtypic immunity (22;23). The goal of my 
study is to explore whether these CTLs can provide lasting protection against multiple serotypes 
after vaccination.  
i. Effector CD8 T cell differentiation  
Naïve antigen-specific CD8 T cells persist at low frequencies and must circulate around the 
body to provide comprehensive surveillance of different lymphoid organs, where cognate 
antigen is presented to T cells by professional antigen presenting cells (APCs)(24). When naïve 
CD8 T cells recognize cognate antigen and become activated, they undergo rapid clonal 
expansion and differentiate into effector (TEFF) cells which can produce cytokines such as 
interferon-γ (IFN-γ), tumor-necrosis factor (TNF) or interleukin 2 (IL-2). Most CD8 T cells also 
gain lytic function and express molecules such as granzymes and perforin (25).  
During infection the pool of activated CTLs becomes highly heterogeneous in terms of 
phenotypic markers (26;27). The IL-7 receptor α chain (CD127), and killer cell lectin-like 
receptor G1 (KLRG-1) are often used to distinguish TEFF cell subsets (28;29). Activated CD8 T 
cells downregulate CD127 and proliferate into the early effector cells (EECs, KLRG-1loCD127lo). 
During clonal expansion some TEFF cells upregulate KLRG-1 and acquire a terminally 
differentiated phenotype (KLRG-1hiCD127lo). Many of these CTLs undergo apoptosis after the 
infection is cleared. A subset of TEFF cells can re-express CD127 and acquire a memory 
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precursor phenotype that is KLRG-1loCD127hi, indicating that they can further differentiate into 
long-lived memory cells. Nevertheless, it should be noted that neither KLRG-1 nor CD127 is 
sufficient or necessary to determine the fate decisions of TEFF cells (30;31). The heterogeneity 
of the TEFF cell population has been further examined at single-cell level. Some studies suggest 
that the fate of TEFF cells is determined by asymmetric distribution of surface and intracellular 
molecules during the first cell division (32). Others suggest TCR affinity determines whether 
CD8 T cells undergo symmetric or asymmetric cell division and thus controls the phenotype of 
the daughter cells (33). However, studies using single-cell transfer or ‘DNA-barcoding’ show that 
individual cells bearing the same TCR can yield progeny cells with disparate fates, and exhibit 
highly diverse abilities to proliferate and give rise to progeny with heterogeneous phenotypic 
markers (34-37).  
The plasticity of TEFF cell differentiation underscores the importance of extrinsic signals which 
can come from a variety of sources including antigen stimulation (signal 1), co-stimulation 
(signal 2) and inflammatory cytokines (signal 3). Studies show that the abundancy and duration 
of available antigens are not only in proportion to the magnitude of clonal expansion, but also 
affect memory differentiation of TEFF cells (38;39). A high frequency of naïve CD8 T cell 
precursors (40;41), or activation of naïve T cells during a late stage of infection (42), typically 
leads to decreased expansion and preferential differentiation towards a memory phenotype.  
Costimulatory molecules play important roles during different stages of the CD8 T cell response, 
including activation, expansion, and memory formation (43;44). The interactions between CD28 
and CD80/CD86 during priming are crucial for the generation of a successful effector CD8 T cell 
response, especially for T cells with low affinity receptors (45). Costimulation through CD28, 
CD27, 4-1BB and OX40 promotes survival by increasing the expression of anti-apoptotic 
molecules (46). For instance, incorporation of 4-1BB into a vaccine vector increased the 
numbers of antigen-specific CD8 T cells in mice after IAV infection and prolonged the duration 
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of protection, by promoting the survival of activated CD8 T cells (47). Costimulatory signals also 
contribute to the generation of memory CD8 T cells in variety of infection models (45). For 
instance, a recent study demonstrates that NP-specific CD8 T cells are able to receive a signal  
via CD27 by interacting with CD70-bearing dendritic cells (DCs) at late stage after primary 
infection, which facilitate the development of memory cells with high proliferative capacity (48).  
The milieu of pro-inflammatory cytokines that are produced upon innate immune recognition of 
pathogen-associated molecular patterns (PAMPs) can also influence the properties of 
developing CD8 TEFF cells (49). IL-12, IFNγ, type I IFN or IL-27 can augment the expansion as 
well as the contraction of TEFF cells, by increasing the ratio of terminally differentiated cells to 
memory precursors (29;50). Recent studies also show that IL-1 can significantly increase clonal 
expansion and augment the effector functions of antigen-specific CD8 T cells (51). In addition, 
autocrine IL-2 production is essential for TEFF cell expansion, differentiation and survival. 
Studies show that some TEFF cells which maintain high expression of the high-affinity IL-2 
receptor α chain (CD25) undergo extensive proliferation and become terminally differentiated, 
while TEFF cells with low expression of CD25 preferentially become memory cells (52;53). 
ii. Circulating memory CD8 T cells 
A majority of TEFF cells undergo apoptosis as the pathogen is cleared. This process is 
determined by the balance between pro-survival molecules such as B-cell lymphoma 2 (Bcl-2) 
or myeloid cell leukemia 1 (Mcl-1), and pro-apoptotic molecules such as Bim or Noxa. Activation 
of downstream effector molecules caspase-3 and -7 can also be regulated by the external 
signals that are received by TEFF cells (54;55). Contraction of the CD8 T cell response leaves 
small numbers of long-lived memory CD8 T cells which rely on IL-7 and IL-15 for survival and 
homeostatic turnover (45). A key feature of these memory cells is their ability to respond rapidly 
to re-encounter of antigen by acquiring effector functions and generating secondary TEFF cells. 
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Antigen-specific memory cells persist at higher frequencies than naïve CD8 T cells, and mount 
more robust secondary responses after reinfection (56). 
The memory CD8 T cell pool can be divided into different subsets based on their phenotype, 
function and location. There are two broad subsets of memory CD8 T cells in the circulation 
which are central memory T (TCM) cells and effector memory (TEM) cells (57). The lineage 
decisions between TCM and TEM cells can be regulated by early signals such as antigen 
availability, costimulation and cytokines (58). TCM cells have high expression of CD62L and 
CCR7 which facilitate the homing to secondary lymphoid organs, while TEM cells lacking these 
two markers are predominantly found in peripheral tissues (59). Transmigration of TCM cells into 
the peripheral lymph nodes is mediated by interactions between CD62L and peripheral node 
addressin (PNAd) on high endothelial venules (HEVs), which enables the tethering and rolling of 
T cells along HEVs (60). CCR7 then engages with HEV-associated chemokines such as CCL21, 
which leads to the activation of lymphocyte function-associated antigen 1 (LFA-1) on T cells. 
The interaction between LFA1 with intercellular adhesion molecules (ICAMs) on the HEVs 
results in firm arrest of T cells and their transmigration into the lymph node parenchyma. 
Functionally, TCM cells have greater proliferative potential and produce IL-2 upon recall, 
whereas TEM cells constitutively display effector functions such as cytotoxicity (59). Conversion 
can occur between these two subsets during memory development and maintenance (59). 
Importantly, a recent study used adoptive transfer of individual cells to show that TCM cells have 
self-renewal capacity, as well as multipotency to generate phenotypically diverse progeny 
across serial adoptive transfers and repeated infections (60). 
iii. Tissue-resident memory CD8 T cells  
In addition to the two subsets of circulating memory CD8 T cells, recent studies identified a third 
population of virus-specific memory CD8 T cells that locate in peripheral  tissues and do not re-
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enter circulation. These CTLs remains at the site of potential re-infection, such as a mucosal 
tissue, and are therefore referred to as tissue resident memory T (TRM) cells (61;62). Large 
numbers of TRM cells are generated in the lungs after local, but not systemic, IAV infection (63). 
Microarray analysis revealed a core transcriptional signature of this population that is distinct 
from TCM or TEM cells (64). Most TRM cells are characterized by their high expression of the 
activation marker CD69 and αEβ7 integrin CD103, but are devoid of CD62L and CCR7 
expression. Studies have shown that TRM cells develop from the KLRG-1lo subset of TEFF cells in 
response to tissue-derived signals, such as the cytokine transforming growth factor β (TGFβ)  
(64). This thesis will address the role of TGFβ in the generation and/or maintenance of TRM cell 
population.  
Previous studies have shown that TGFβ controls the expression of CD103 on TRM cells and 
therefore promotes interactions with E-cadherin expressed on epithelial cells, which is important 
for retention in mucosal tissues (65-68). The role of prolonged presentation of cognate antigen 
after acute infection remains controversial, and may promote the differentiation and/or 
maintenance of TRM cells in the lung (65;69), but is not required in the intestine or skin (70;71). 
IL-15 also plays a role in the formation and survival of TRM cells in the skin (64). In addition, 
downregulation of Krüppel-like Factor 2 (KLF2) and its target, the receptor for sphingosine 1-
phosphate (S1P1), is mediated by TGFβ, IL-33 and TNF via the phospophatidylinositol-3-OH 
kinase (PI3K)/Akt pathway, which prevents the egress of lymphocytes from inflamed tissues and 
is necessary for the development of TRM cells (72).  
Several studies have shown that TRM cells mediate critical protection against local challenge in 
different tissues including the lungs (73-75). These cells are poised in the tissues to provide 
frontline defenses during the earliest phase of re-infection, by rapidly recognizing and killing 
pathogens, or recruiting other types of immune cells. A study from our lab has shown that TRM 
cells play a crucial role in heterosubtypic immunity against IAV infections by decreasing viral 
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load (90). The recruitment of circulating memory CD8 T cells to the lungs is not necessary for 
protection, but it enables the replenishment of different subsets of cells in the memory 
compartment (90). On the other hand, a recent study showed that re-challenge of TRM cells can 
quickly induce an anti-viral state locally in the skin or female reproductive tract (FRT) after re-
challenge (74;75). These cells can induce the expression of vascular cell adhesion molecule-1 
(VCAM-1) on vascular endothelium by secreting IFN-γ upon re-activation, which promotes the 
recruitment of circulating memory CD8 T cells and B cells. Also, cytokines such as TNF and IL-2 
are produced by activated TRM cells to facilitate DC maturation and natural killer (NK) cells 
activation.  
Although virus-specific CD8 T cells can provide cross-protection between different IAVs, eliciting 
memory populations with the properties that are required for immunity is a major challenge for 
vaccination. Optimal protection requires a combination of circulating memory CD8 T cells, which 
move through the bloodstream to migrate around the body, as well as TRM cells which mount 
rapid responses to reinfection by remaining near the site of inoculation (Figure 1-1). The goal of 
my work is to identify signaling molecules that influence CD8 T cell differentiation and the 
production of heterogeneous memory populations which provide heterosubtypic immunity, 
including TRM cells. 
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Figure 1-1 
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Figure 1-1 Different subsets of virus-specific CTLs participate in heterosubtypic 
immunity. 
A. During primary IAV infection, dendritic cells (DCs) migrate from the infected lungs to the 
mediastinal lymph node (MLN). Naïve CD8 T cells recognize their cognate antigen which is 
presented by DCs. Upon activation, virus-specific CD8 T cells undergo clonal expansion and 
differentiate into TEFF cells which migrate into the lungs and kill infected epithelial cells. Since 
several days pass before TEFF cells arrive in the lung, some virus can reach the alveoli and 
cause pathology. Residual CTLs remain in the lungs after viral clearance and become TRM cells.  
B. Upon secondary challenge, TRM cells are located in the airways and rapidly kill newly infected 
epithelial cells. Since the virus is rapidly cleared from the airways, low viral titers reach the 
alveoli. Some TCM are reactivated in the MLN, but very few nascent TEFF cells enter lungs and 
cause mild pathology 
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Mice  
C57BL/6 mice were purchased from Charles River (Wilmington, MA). Smad4flox/flox mice were 
obtained from Dr. Garvy (University of Kentucky), which were crossed with mice that express 
Cre-recombinase under the control of the distal Lck (dLck) promoter (SKO) (74), as well as OTI 
TCR transgenic mice (75). The dLck-Cre TGFβRIIflox/flox mice (TKO) were generously supplied Dr. 
M. Bevan (University of Washington). The mice with two mutations, dLck-Cre 
Smad4flox/flox TGFβRIIflox/flox mice (ST-DKO), were generated by cross-breeding. Mice were 
housed at University of Connecticut Health Center in accordance with institutional guidelines. 
Viral and Bacterial infections 
Virus stocks were grown in fertilized chicken eggs and titers determined as described previously. 
Mice were anesthetized by ketamine/Xylazine and were infected with 103 plaque-forming unites 
(PFU) of X31-OVA (H3N2 serotype) or WSN-OVA1 (H1N1 serotype) by intranasal (i.n.) 
inoculation. For secondary infection, primed mice were challenged with 5x103 PFU of WSN-
OVA1 or X31-OVA i.n.  
Mixed bone marrow chimeras  
Lethally irradiated mice (1000 rads) were reconstituted with 5x106 bone marrow cells from 
congenically marked mutant and control mice (1:1 ratio). To eliminate radio-resistant cells 
200μg anti-CD8 antibodies (2.43) were given by i.v. injection 2 days after transfer. Mice were 
maintained for 6-8 weeks before IAV infection.  
Transfer experiments 
Naïve CD8 T cells from donor mice were sorted for low CD44 expression. Recipient mice 
received mixed populations of congenically marked mutant and/or wild type donor cells (mixed 
1:1, 104 cells total). For proliferation assays, donor cells were labeled with 10 μM CFSE 
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(carboxyfluorescein diacetate succinimidyl ester) at 37°C for 8 minutes before transfer. 
Recipient mice received 106 donor cells 2 days before IAV infection. 
Sample preparation for flow analysis 
Single-cell suspensions were made from spleens and lymph nodes, with red blood cells lysed 
with triammonium chloride (TAC). Lungs were digested with 150 U/ml collagenase (Life 
Technologies) in RPMI medium 1 mM MgCl2, 1 mM CaCl2, and 10% fetal bovine serum (FBS) 
and enriched by 44/67% Percoll gradients. Washed lymphocytes were stained with anti-CD8 
and NP366-374 H2-Db tetramers for 1 hour at room temperature. The staining of all other surface 
markers was done at 4°C for 30 minutes. Fluorochrome-conjugated antibodies against the 
following antigens were used for flow cytometry: CD8α (53-6.7), CD45.1 (104), CD45.2 (A20), 
KLRG-1 (2F1), CD127 (A7R34), CD44 (IM7), CD69 (H1.2F3), CD103 (2E7), CD62L (MEL-14), 
CD25 (PC61). CCR7 expression was analyzed using CCL19 conjugated to human Ig and Alexa 
Fluor 488-conjugated anti-human IgG (Life Technologies). For intravascular staining mice were 
injected with 3mg anti-CD8β antibodies in 300μL PBS and sacrificed 5 min later. Caspase 
activity was measured with Vybrant FAM Caspase-3 and -7 Assay Kits (Invitrogen). For 
assessment of mitochondrial membrane potential, cells were incubated in complete growth 
medium for 15 minutes at 37 °C with 100 nM MitoTracker Orange CMTMRos (Invitrogen), 
followed by washing with cold PBS and staining of surface markers. Samples were run on a 
LSR-II flow cytometer (BD) and analyzed with Flowjo software (Tree Star Inc.). 
Intracellular Staining and Phospho-flow 
For cytokine analysis, lymphocytes were incubated with SIINFEKL peptide (1μg/ml) in the 
presence of Brefeldin A for 5 hours at 37°C and analyzed with Cytofix/Cytoperm Kit (BD 
Pharmingen). For BrdU analysis, BrdU was injected intraperitoneally (1mg in 200μl PBS), and 
lymphocytes were analyzed 3–6 hours later using a BrdU kit (BD Pharmingen). The Foxp3 
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staining buffer set (eBioscience) was used for intracellular staining of transcription factors using 
antibodies to T-bet (eBio4B10), Eomes (Dan11mag), Bcl-2 (3F11) (eBioscience). 
Phospho-flow analysis were performed directly ex vivo using spleens that were harvested from 
recipient mice at indicated time points and mashed in 2% paraformaldehyde (PFA). Fixed cells 
were permeabilized with ice-cold 100% methanol and stained with antibodies against p-S6 
Ser235/236 (Cell Signaling Techonologies). For in vitro stimulation, splenocytes were harvested 
from recipient mice and rested in tissue culture media with 1% FBS for 3 hours. The cells were 
stimulated with 2ng/ml IL-12 p70 (Biolegend) for 1 hour or 5ng/ml IL-2 (eBioscience) for 30 
minutes. After fixation with 2% PFA cells and permeabilization with methanol, cells were stained 
with anti-p-S6 Ser235/236, and anti-p-STAT4 Tyr693 or anti-pSTAT5 Tyr694 antibodies (BD 
Pharmingen). 
Confocal microscopy 
Tissues were fixed with 1% PFA and stained with biotinylated Abs to epithelial cell adhesion 
molecule (EpCAM) or B220. After washing the cells were stained with streptavidin–Pacific 
Orange (Life Technologies) and a cocktail of antibodies including PE-conjugated anti-CD45.1 
(eBioscience), anti-CD103 Alexa Fluor 647 (BioLegend), KLRG1 Alexa Fluor 488 (BD 
Pharmingen), and CD31 Pacific Blue (Life Technologies). Images were recorded on a Zeiss 
LSM 780 confocal microscope with the Zeiss ZEN 2012 digital imaging suite and an inverted 
Axio Observer Z1 with argon diode, and HeNe lasers using Plan-Neofluar 310/numerical 
aperture 0.5 and 320/numerical aperture 0.5 objectives. Imaris suite (Bitplane) was used for 
background subtraction and colocalization. 
RNA-Seq and bioimformatics 
C57BL/6 mice received mixed populations of 104 CD45.1 OTI-WT and CD45.1.2 OTI-SKO cells 
(1:1 ratio) by trail vein injection and were infected with X31-OVA 2 days later. Splenocytes were 
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harvested at 6 dpi from a total of 9 mice, and were pooled into 3 samples. CD45.1+ donor cells 
were positively enriched by biotinylated anti-CD45.1 antibody (Biolegend) and anti-biotin 
Microbeads (Miltenyi Biotec) on autoMACS machine. The enriched cells were stained with 
antibodies against CD45.1, CD45.2, CD44, CD8, CD127, KLRG-1, and CD103 before sorting 
on a FACSAria II (BD). RNA was extracted from sorted cells with an RNAeasy Plus Mini Kit 
according to the manufacturer’s protocol (Qiagen). 
RNA samples were sent to Otogenetics Cooperation for RNA-Sequencing. The data sets were 
analyzed with Tophat2 mapping (DNAnexus). Expression levels were measured with Cuffilinks 
software (DNAnexus) and differential expression analysis was done with Cuffdiff software 
(DNAnexus). Genes with transcriptional changes over two folds (Log2 fold change >1 or <-1, 
p<0.05, false discovery rate<0.05) were selected for Ingenuity pathway analysis (Qiagen) and 
Gene set enrichment analysis (Broad Institute). Heatmaps were generated by Gene E software 
(Broad Institute).  
Metabolic Assays 
B6 mice recieved 105 or 106 donor cells 2 days before infection with x31-OVA. Lymphocytes 
were harvested from the mediastinal lymph nodes (MLNs) at 3.5dpi or spleens at 6dpi and 8dpi. 
Donor cells were positively enriched using biotinylated anti-CD45.1 antibody and anti-biotin 
microbeads. The enriched cells were stained with CD45.1, CD45.2, CD44, CD8, CD127, KLRG-
1, and CD103 antibodies and sorted on a FACSAria II. CD45.1+ donor cells were positively 
enriched by biotinylated anti-CD45.1 antibody (Biolegend) and anti-biotin Microbeads (Miltenyi 
Biotec) on autoMACS machine. The enriched cells were stained with antibodies against CD45.1, 
CD45.2, CD44, CD8, CD127, KLRG-1, and CD103 before sorting on a FACSAria II (BD). 
For extracellular flux assays, sorted cells were seeded at 2x105 cells per well on Cell-Tak 
(Corning) coated 96-well plates, and rested for 1 hour at 37°C without CO2. Oxygen 
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consumption rate (OCR) and extracellular acidification rate (ECAR) were measured on XF-96 
Extracellular Flux Analyzer (Seahorse Biosciences). Briefly, mito stress tests were done in 
DMEM containing 2mM glutamine, 1mM sodium pyruvate and 25mM glucose. OCR was 
measured under basal conditions and in response to 4μM oligomycin, 0.5μM fluorocarbonyl 
cyanide phenylhydrazone (FCCP) and 0.5μM rotenone/antimycin A. 200μM Etomoxir, 50μM 
BPTES or 50μM UK5099 (Sigma) was used as inhibitors of oxidative phosphorylation. 
Glycolysis stress tests were done in glucose- and pyruvate-free DMEM. ECAR was measured in 
response to 10mM glucose, 4μM oligomycin and 50mM 2-DG during the assay. 
Statistical analysis 
Experiments were repeated 2 or 3 times using 3-5 animals per group. Statistical significance 
was determined using an unpaired two-tailed Student t test. Comparisons that were used to 
generate p values are indicated by horizontal lines in the figures. A p value<0.05 was 
considered statistically significant. 
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Abstract 
Although heterogeneous populations of memory CD8 T cells participate in immunity against IAV 
infection, the signaling pathways that are responsible for this heterogeneity are poorly defined. 
An important regulatory pathway for activated CTLs is controlled by TGFβ, which reduces the 
numbers of terminally differentiated TEFF cells in infected tissues and is required for CD103 
expression on TRM cells. When genetically-modified mice were used to prevent expression of 
the TGFβ receptor on activated CTLs during IAV infection, increased numbers of KLRG1+ TEFF 
cells collected in the infected lungs, while TRM cells were absent during the late stage of the 
response. To define which signaling pathway is required for CD103 expression on TRM cells, we 
performed similar experiments with CTLs lacking the downstream signaling intermediate Smad4. 
We found that Smad4 was required for the formation of KLRG1+ TEFF cells, while TCM cells had 
no requirement for TGF-β. A large population of CTLs showed signs of arrested development in 
the absence of Smad4, including aberrant CD103 expression. Imaging studies showed that 
these signaling pathways alter the distribution of virus-specific memory CD8 T cells in the lungs, 
but do not affect cytokine production. Smad4-deficency caused slightly delayed viral clearance 
after primary IAV infection, but was not required for protective immunity upon reinfection with 
another strain. Our data show that TGFβ and Smad4 are required for normal differentiation of 
multiple subsets of virus-specific CTLs, including KLRG1+ TEFF cells, CD62L+ TCM cells and 
CD103+ pulmonary TRM cells.  
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Introduction 
TGFβ is a cytokine with multiple functions, including regulation of immune cells (76). A latent 
precursor must be cleaved by proteases in the tissue matrix to release an active 25-kDa peptide 
which is capable of receptor binding (77). TGFβ can also be activated by the NA enzymes of 
some viruses and is produced in large quantities in the lungs during IAV infection (78). A 
published study showed that some highly pathogenic H5N1 strains of IAV do not activate latent 
TGFβ very effectively and that ectopic expression of TGFβ prolonged the survival of H5N1-
infected mice (79). These data suggest that TGFβ may play a role in protecting the host from 
IAV pathogenesis.  
TGFβ is a suppressive cytokine and master regulator of diverse populations of immune cells, 
including DCs, NK cells and macrophages. In addition, TGFβ inhibits proliferation of B and T 
cells and can induce apoptosis (80). Other important functions include roles in inducing IgA 
class switching (81) and regulating CD4 T cell differentiation (80). TGFβ suppresses the 
formation of Th1 and Th2 subsets and promotes Th17 development by inducing RORγt and 
suppressing expression of Eomesodermin (Eomes) (82). In addition, TGFβ is crucial for the 
induction of the Forkhead box p3 (Foxp3) gene during development of regulatory T (Treg) cells 
(83;84).  
How TGFβ regulates the CD8 T cell response is less well defined, but recent studies have 
shown that naïve CD8 T cells undergo enhanced proliferation in a lymphopenic environment 
and acquire an activated CD44hiCD62Llo phenotype when the TGFβ receptor (TGFβRII) is not 
expressed (85). During Listeria Monocytogene infection, TGFβRII deficiency resulted in the 
selective accumulation of KLRG1+ TEFF cells (86). In addition, TGFβ induces expression of 
e7 integrin (CD103) which is essential for the generation and/or residence of TRM cells in the 
lungs, thus indicating a role in protection (64-66). In this thesis we examined the role of TGFβ 
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during tissue localization of anti-viral CTLs and protective immunity to IAV infection. We also 
focus on the intracellular signaling molecule Smad4, which acts downstream of the receptors for 
multiple members of the TGFβ cytokine family. 
Smad-dependent TGFβ signaling pathways 
The TGFβ receptor is comprised of two subunits (TGFβRI and TGFβRII), which are 
serine/threonine kinases (87). Ligand binding brings TGFβRII in close association with TGFβRI, 
allowing phosphorylation and signal transduction via multiple pathways (88). The canonical 
signaling pathways are mediated by Sma and Mad-related (Smad) transcription factors, which 
are well-studied in cancer (87) and the immune system (80). Eight Smad proteins have been 
identified in vertebrates, including the multiple receptor activated Smad proteins (i.e. Smad1, 2, 
3, 5, and 8), which form complexes with a shared adaptor (Smad4), as well as two inhibitory 
Smads (Smad6 and 7) which can prevent signal transduction (87;89). At the basal state, R-
Smads are predominantly located in the cytoplasm and use cytoplasmic anchors to interact with 
the Smad Anchor for Receptor Activation (SARA). The adaptor protein Smad4 is evenly 
distributed throughout the cells and constantly transported between the cytoplasm and nucleus. 
In response to activation, the TGFβ receptor phosphorylates R-Smad2 and R-Smad3, which 
dissociate from SARA and bind to Smad4 for translocation into nucleus. The phosphorylated 
Smad proteins form complexes which attach to Smad-binding elements (SBE) in the promoters 
of the target genes. DNA binding is mediated by a β-hairpin structure at the N-terminal Mad-
homology 1(MH1) domain that is conserved in Smad4 and all R-Smad proteins. Transcriptional 
activity depends on interactions with other transcription factors, which enable high affinity 
binding to DNA in selected target genes. Also, depending on these associated co-factors, the 
complexes either recruit coactivators, such as p300 and cAMP-response element-binding 
protein (CREB) binding protein (CBP), or corepressors such as histone deacetylases (HDACs). 
Such interactions are crucial for the diverse functions of TGFβ. When R-Smads are 
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dephosphorylated in the nucleus, they dissociate from Smad4 and are exported to the 
cytoplasm for another round of signal transduction. Smad4 is not always required for 
transcriptional activity of the Smad complex. In Smad4-deficient cancer cells TGFβ treatment 
can induce translocation of pSmad2/3 into the nucleus, though such complexes do not have 
transcriptional activity (90). Another transcription factor, transcriptional intermediatory factor 1γ 
(TIF1γ), can also bind to phosphorylated Smad2/3 in hematopoietic cells and is involved in 
erythrocyte differentiation (91). Development for invariant natural killer T cells (iNKTs) are 
controlled by at different stages by Smad4 and TIF1γ (92). A recent study revealed that TIF1γ 
antagonizes Smad signaling by mono-ubiquitinating Smad4 which causes dissociation of the 
Smad2/3/4 complex (93). 
Smad-independent TGFβ signaling 
TGF-β receptor can also signal through a variety of pathways that are independent of Smad 
proteins, which have been extensively studied in other cell types, yet little is known about their 
functions in immune cells (87;94). TGFβ can activate various branches of mitogen-activated 
protein kinase (MAPK) pathways, including Erk, c-Jun N terminal kinases (JNKs) and p38 (95). 
Phosphorylated TGFβ receptors recruit Grb2/Sos and Ras to activate the Raf/MEK/Erk cascade, 
which is essential for epithelial to mesenchymal transition (EMT) (96). Binding of TNF receptor-
associated factor 6 (TRAF6) to activated TGFβ receptors induces the lysine-63 (K63)-linked 
polyubiquitination of TRAF6, which recruits TGF-β-activated kinase 1 (TAK1) to activate JNKs, 
or p38 via MKK4 or MKK3/MKK6 respectively. These pathways are important for TGFβ-induced 
apoptosis and EMT (97;98). The phosphatidylinositol 3-kinase (PI3K)/Akt pathway can also be 
activated by the TGFβ receptor (99), and contributes to TGFβ-driven EMT. The mechanism may 
require mammalian target of rapamycin (mTOR) activity, which is a key regulator of protein 
synthesis (100). The PI3K/Akt/mTOR pathway antagonizes Smad-mediated effects via various 
mechanisms. For example, Akt activation protects cancer cells from TGF-β-induced growth 
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arrest and apoptosis (101). In addition, TGFβ can activate small Rho-like GTPases including 
Rho-A and Cdc42, which promotes the formation of actin stress fibers and dissolution of tight 
junctions during the EMT (102). These Smad-independent TGFβ signaling pathways are poorly 
understood in the immune system.  
This thesis explores to the role of TGFβ and Smad4 during the contraction of the KLRG-1+ TEFF 
response in the lungs and/or induction of CD103 expression on TRM cells (103). Using flow 
cytometry and fluorescence microscopy, we compared the phenotypes and locations of effector 
and memory CD8 T cells when TGFβRII or Smad4 were absent. In addition, we examined the 
role of TGFβ and Smad4 in heterosubtypic immunity by comparing host survival after primary 
and secondary IAV infections. 
Major goals for chapter 3: 
Aim 1.1 To determine whether TGFβRII or Smad4 deficiency alters the phenotypes and/or 
functional properties of virus-specific CD8 T cells after IAV infection 
Aim 1.2 To determine whether Smad4-dependent and -independent TGFβ signaling impacts 
the localization of virus-specific CD8 T cells after IAV infection 
Aim 1.3 To examine whether TGFβRII or Smad4 is required for protective immunity 
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Results  
TGF-β suppresses terminal differentiation of KLRG1+ TEFF cell. 
Genetically-modified mice were used to determine how TGF-β alters the CTL response to IAV 
infection. Chimeric mice were made with mixed bone marrow cells from dLck-Cre TGFβRIIflox/flox 
(TKO) mice (85) and their WT littermates (lacking Cre or flox sites). This approach ensures that 
mutant and WT CTLs are exposed to identical concentrations of antigen and inflammation 
during infection. After eight weeks the secondary lymphoid organs contained approximately 
equal numbers of WT and TKO CD8+ T cells. Large percentages of the TKO cells expressed 
CD44 at high levels and downregulated CD62L, including KLRG-1 expression on some cells 
(Figure 3-1A). This phenotype was consistent with enhanced homeostatic proliferation after 
radiation (85).  
To analyze the CTL response to viral infection, chimeric mice were infected with X31-OVA and 
analyzed for NP-specific CTLs by MHC class I tetramer analysis. There were larger numbers of 
TKO cells in the lungs and spleens 10 days post infection (dpi), as compared to the controls (Fig. 
3-1B). Consistent with the literature (65;86), our phenotypic data showed that high frequencies 
of TKO cells expressed KLRG1, whereas CD103+ cells were almost completely absent (Fig. 3-
1C). These data suggest that KLRG1+ TEFF cells and TRM cells respond to TGF-β in very 
different ways after IAV infection. 
TGF-β suppresses cell proliferation during the TEFF response.  
Because some CD8 T cells were non-specifically activated in the irradiated mice, we performed 
adoptive transfer experiments with donor cells from OTI TCR transgenic mice that express an 
antigen receptor that is specific for the SIINFEKL peptide from the chicken ovalbumin (OVA) 
gene (107). Donor cells from OTI-TKO and wild type littermates were sorted for low CD44 
expression. The recipient animals received mixed populations of congenically marked OTI-TKO 
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and OTI-WT cells 48 hrs before infection. The kinetic studies show that large numbers of 
KLRG1+ TEFF cells accumulated in the lungs and spleens in the absence of TGF-β regulation 
(Figure 3-2A).  
To determine whether the phenotypic variation was due to altered cell proliferation, donor cells 
from OTI-WT and OTI-TKO mice were labeled with Carboxyfluorescein succinimidyl ester 
(CFSE) before transfer. The mice were infected with X31-OVA and analyzed by flow cytometry 
3.5 dpi (Fig. 3-2B). Other recipients were given a single injection of BrdU on 6, 8, or 10 dpi and 
donor CTLs were analyzed 3–6 h later (Fig. 3-2C). The CFSE analysis showed no difference in 
cell division 3.5 dpi (Fig. 3-2B), and the CTLs from each group of mice incorporated BrdU at 
very similar rates 6 dpi (Fig. 3-2C). At later time points the percentages of BrdU+ CTLs in the 
OTI-TKO population were much higher than the OTI-WT cells (Fig. 3-2C). These studies show 
that the virus-specific CTLs underwent prolonged proliferation in the absence of TGF-β 
regulation. Similar levels of activated caspases-3/7 (Fig. 3-2D) and pro-survival molecule Bcl-2 
were detected in the transferred cells (Fig. 3-2E), which indicated that TGF-β did not 
substantially alter cell survival. 
Similar to the tetramer+ CTLs from chimeric mice, CD103 was absent on OTI-TKO cells 30 dpi 
(Fig. 3-3A). Only small percentages (and numbers) OTI-TKO cells expressed CD69 in the lungs 
(Figure 3-3A and 3-3B hatched shading), indicating limited production of pulmonary TRM cells 
without CD103. In contrast, a substantial proportion of the OTI-WT cells co-expressed CD103 
with CD69 in the lungs, indicating that some TRM cells were present 30dpi (Figure 3-3A, Figure 
3-3B black shading). These experiments confirm that TGF-β plays a critical role in the 
development and/or maintenance of pulmonary TRM cells. 
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Most long-lived KLRG1+ CTLs remain in the vasculature 
We have shown that activated CTLs express altered homing receptors in the absence of TGF-β 
regulation, including the formation of a large KLRG1+ subset. Because the distribution of virus-
specific memory CD8 T cells in the lungs is very important for immunity (61), we used confocal 
microscopy to compare the distribution of OTI-TKO and OTI-WT cells during the recovery from 
IAV infection (Fig. 3-4A). Naive CD8 T cells (CD44lo) were sorted from congenically marked 
OTI-TKO and OTI-WT mice and transferred to separate recipients. The recipient mice were 
infected with X31-OVA 48hrs later and the lungs were analyzed by confocal microscopy 10 and 
30 dpi, to compare the distribution of transferred CTLs in each group (Figure 3A). Low 
magnification images show the tissue structure (left panels) with transferred cells shown in blue. 
CTLs in the marked sub-regions (white boxes) are shown at higher magnification with (i) KLRG1 
and (ii) CD103 expression, identified using the co-localization function of the Imaris™ software 
(white color). EpCAM-specific antibodies were used to define the outer margins of the large 
airways (marked with red dashed lines in panels on the right side). Large numbers of OTI-TKO 
cells and some OTI-WT cells expressed KLRG1 during the acute stage of the infection and 
were located in the tissue surrounding the alveoli (middle column). In contrast, substantial 
numbers of CTLs from OTI-WT mice expressed CD103 in the airways after the contraction of 
the TEFF cell response (right column).  
Substantial numbers of OTI-TKO cells expressed KLRG1 30dpi, indicating that some terminally 
differentiated CTLs maintained the capacity for long-term survival (Figure 3-2). These long-lived 
KLRG1+ CTLs universally expressed CD11a at high levels (Figure 3-4B), showing that they did 
not reach the lumen of the airways, where high concentrations of host proteases cleave CD11a  
from the cell surface (104). We further examined where these phenotypically distinct subsets of 
CTLs were located after infection, using injected antibodies for intravascular staining (105). 
Congenically marked donor cells were transferred 48 h before infection with X31-OVA. On the 
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days shown, antibodies to CD8β were given by i.v. injection 5 min before sacrifice. Secondary 
staining with anti-CD8a was used to identify CTLs in the tissues. This study showed that some 
KLRG1+ CTLs from both OTI-TKO and OTI-WT mice were protected from the injected 
antibodies 8 dpi (Figure 3-4C, top row), and therefore entered the lung parenchyma during 
acute viral infection (106). In contrast, very few KLRG1+ CTLs were protected from the injected 
antibodies 40 dpi (Figure 3-4C, bottom row), indicating that “terminally differentiated” CTLs were 
poorly equipped for long-term survival in peripheral tissues. A small number of ‘blood-resident’ 
memory CD8 T cells maintained KLRG1 expression 40 dpi.  
Previous studies have shown that IAV infection induces long lived CTLs that express CD103 in 
the lungs, which is a marker of TRM cells (61;63). CD69 is another marker for TRM cells which is 
not regulated by TGF-β (70). Vascular staining showed that a substantial population of OTI-WT 
CTLs co-expressed CD103 together with CD69 in the lung parenchyma and were therefore TRM 
cells (Figure 3-4D). In contrast, only small percentages of OTI-TKO cells were located in the 
lung parenchyma (7%) and very few expressed CD69 (1.75% of total). The frequencies of CTLs 
that expressed CD69 in the bloodstream were similar between TKO and WT populations (Figure 
3-4D). Taken together, our data show that pulmonary TRM cells require TGF-β during prolonged 
residence in the lungs. 
Smad4 is required for the formation of KLRG1+ TEFF cells 
To determine whether TGFβ regulates CTL response through Smad-dependent or Smad-
independent signaling pathways, we used mice with T cell-specific deletion of Smad4 (dLck-Cre 
Smad4flox/flox)(107). Chimeric mice were made with mixed bone marrow cells from SKO mice and 
littermates as WT controls. Naïve CD8 T cells from both SKO and WT donors largely 
maintained a CD44loCD62Lhi resting phenotype and lacked KLRG1 8 weeks after transfer 
(Figure 3-5A). This contrasted with the TKO CTLs which become activated during the 
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reconstitution after irradiation (Figure 3-1A). Additional mice were infected with IAV and 
analyzed by MHCI tetramer staining. Similar numbers of NP-specific CTLs were derived from 
the SKO and WT donor cells 10dpi and 20dpi after IAV infection (Figure 3-5B). Interestingly, 
very few SKO CTLs expressed KLRG1, whereas large percentages of CTLs expressed CD103 
in the lungs and spleen (Figure 3-5C). This showed that anti-viral CTLs developed reciprocal 
phenotypes when the TGFβ receptor, or its downstream signaling molecule Smad4, were 
absent. 
To examine whether the kinetics of the TEFF response were regulated through Smad4, recipient 
mice received mixed populations of CD44lo OTI-SKO and OTI-WT cells 48 hrs before IAV 
infection and flow analysis was used to monitor the numbers of transferred cells at different 
times after infection. There was very little difference in the total numbers of OTI-SKO and OTI-
WT cells at all time points, yet very few KLRG1+ cells were generated in the absence of Smad4 
(Figure 3-6A). We also found no difference in cell proliferation by CFSE-dilution 3.5dpi, or BrdU 
incorporation 6-10dpi (Figure 3-6B, Figure 3-6C). Therefore, the Smad4-deficient CTLs did not 
undergo prolonged proliferation and terminal differentiation after IAV infection, which was in 
complete contrast to the response of CTLs lacking the TGF receptor. The OTI-SKO and OTI-
WT cells expressed activated caspases-3/7 (Figure 3-6D) and pro-survival molecule Bcl-2 
(Figure 3-6E) at similar levels indicating that there was no substantial difference in cell death. 
Pulmonary TRM cells form normally in absence of Smad4 
We next investigated whether Smad4 was required for formation of TRM cells, using CD69 and 
CD103 expression. Despite the fact that CD103 was widely expressed without Smad4, similar 
frequencies and numbers of OTI-SKO and OTI-WT cells co-expressed CD69 with CD103 in the 
lungs 30 dpi (Figure 3-7A, Figure 3-7B black shading). This result indicates that, although TGF-
β plays a critical role in the formation of pulmonary TRM cells, Smad4 is not required. 
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To determine whether Smad4 deletion altered migration of pulmonary CTLs, we used confocal 
microscopy to compare the distribution of OTI-SKO and OTI-WT cells in the lungs after IAV 
infection (Figure 3-8A). Images of the lungs showed similar distributions of OTI-SKO and OTI-
WT cells 10dpi and 30dpi. Substantial numbers of OTI-SKO cells also expressed CD103 in the 
airways after the contraction of the TEFF cell response (right columns), indicating normal 
development/maintenance of pulmonary TRM cells. Flow analysis also showed that most OTI-
SKO cells expressed CD11a at high levels 30dpi, confirming that they did not enter lumen of the 
airways (Figure 3-8B).  
We next used intravascular staining to determine which cells were located inside the blood 
vessels. Similar frequencies of OTI-SKO and OTI-WT cells were found in the blood and tissues 
(Figure 3-8C, Figure 3-8D). Some OTI-WT cells expressed CD103 in the lung parenchyma 
(Figure 3-8C), but not in the spleens (Figure 3-8D) or blood (Figure 3-8C, Figure 3-8D). In 
contrast, CD103 was widely expressed on the OTI-SKO cells, which were equally distributed 
inside and outside of the blood vessels (Figure 3-8C, Figure 3-8D). Similar numbers of OTI-WT 
and OTI-SKO cells expressed CD69 together with CD103 in the lung parenchyma (Figure 3-8C). 
These data indicate that aberrant CD103 expression is not sufficient to increase the size of the 
TRM population in the lungs.  
Smad4 is required for differentiation of central memory T cells 
Since some OTI-SKO cells were located in the blood stream, we also analyzed the transferred 
cells for markers of circulating memory CD8 T cells. Flow analysis showed that large numbers 
of OTI-SKO cells expressed CD103 in the spleen 30 dpi, but lacked CD62L expression 
indicating that they were not typical central memory T (TCM) cells (Figure 3-9A, Figure 3-9B). Yet 
OTI-SKO cells expressed CCR7, which is another marker of TCM cells, at similar levels as 
compared to OTI-WT cells (Figure 3-9C, Figure 3-9D). Because TCM cells require CD62L to 
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access resting lymph nodes via HEVs (108), we analyzed the distribution of transferred cells 
inside the secondary lymphoid organs by confocal imaging (Figure 3-9E). Substantial 
populations of OTI-WT and OTI-TKO cells were distributed in the cortex of the inguinal lymph 
nodes 30 dpi, whereas there were only a few OTI-SKO cells at this location. Still, small 
populations of OTI-SKO cells, which lacked CD62L, were found in the inguinal lymph nodes by 
imaging (Figure 3-9E), indicating that normal CCR7 expression on OTI-SKO cells enabled 
inefficient transendothelial migration in HEVs when CD62L is absent. Therefore Smad4 also 
plays an important role in the development of TCM cells. 
Smad4 has a TGFβ-independent role in the CD8 T cell response 
Since our data show that TGFβ and Smad4 play very different roles in CD8 T cell differentiation, 
we further investigated which pathway was dominant. To address this question, we crossed 
OTI-TKO and OTI-SKO mice to produce progeny lacking both Smad4 and the TGF receptor 
(called OTI-STDKO). Recipient mice received mixed populations of congenically marked donor 
cells from OTI-STDKO mice and wild type littermates 48h before x31-OVA infection.  A kinetic 
study showed decreased numbers of KLRG1+ OTI-STDKO TEFF cells as compared to OTI-WT 
cells in lungs and spleens after IAV infection (Figure 3-10A). No difference in cell proliferation 
was observed either by CFSE dilution or BrdU incorporation between the OTI-WT and OTI-
STDKO cells (Figure 3-10B, Figure 3-10C). These results are in contrast to the experiments 
with CTLs from TGFβRII deficient mice which underwent late proliferation and transitioned to a 
terminally differentiated KLRG1+ phenotype (Figure 3-2). Thus, these experiments showed that 
the mutation in Smad4 was dominant and that the CTL response is regulated by a mechanism 
that does not require the TGFβ receptor.  
Because CD103 was widely expressed on SKO cells, we also examined whether TGFβRII was 
required for CD103 expression when Smad4 was absent. Naïve OTI-WT cells express CD103 
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which is downregulated upon activation. A small number of OTI-WT cells began to re-express 
CD103 in the lungs 8dpi, and the size of this subset gradually increased by memory time points, 
indicating the development of pulmonary TRM cells (Figure 3-11A). Naive OTI-SKO and OTI-
STDKO cells expressed CD103 at slightly higher levels than the OTI-WT cells (Figure 3-11A), 
which was downregulated during TCR stimulation. The OTI-SKO and OTI-STDKO cells both re-
expressed CD103 by 6dpi in the lungs and spleens (Figure 3-11A). Some CTLs expressed 
CD69 together with CD103 indicating that normal numbers of pulmonary TRM cells developed 
when both TGFβRII and Smad4 were absent (Figure 3-11B). In addition large numbers of OTI-
STDKO cells expressed CD103 without CD69 in lungs and spleens (Figure 3-11B). Although 
TGFβ is critical for CD103 expression and development of TRM cells (64;66;85), these data 
showed that widespread re-expression of CD103 on OTI-SKO and OTI-STDKO cells, did not 
require the TGFβ receptor and suggests that Smad4 be a suppressor of CD103 expression.  
We also determined whether Smad4 regulates CD62L expression independently of TGFβRII. 
While high frequencies of OTI-STDKO cells aberrantly expressed CD103 in the spleens and 
ILNs, very CTLs re-expressed CD62L, while CCR7 expression not undisrupted (Figure 3-11C). 
Therefore, the OTI-STDKO cells had a similar phenotype to OTI-SKO cells, which suggests that 
Smad4 has a TGFβRII-independent role in effector and memory CD8 T cell differentiation.  
Delayed viral clearance by Smad4-deficient CTLs after primary infection 
Experiments with a dominant-negative form of TGFβRII have shown that TGFβ can inhibit 
cytokine production by antigen-specific CD8 T cells (23). We also compared the effector 
functions of OTI-WT, OTI-TKO, and OTI-SKO cells after in vitro stimulation. Each cell population 
produced large quantities of IFN-γ and TNF after peptide stimulation, confirming that they were 
functional TEFF cells, despite the differences in CD103 and KLRG-1 expression (Figure 3-12).  
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To determine whether TGFβ or Smad4 deletion altered immunity against IAVs, mice were 
infected with a sub-lethal dose of IAVs, and re-challenged with a serologically distinct strain 30 
days after primary infection. Similar changes in body weight showed that the TKO mice 
recovered from primary IAV infection with similar kinetics as WT animals. In contrast, the SKO 
mice recovered from infection with delayed kinetics (Figure 3-13A&B). The ST-DKO mice 
showed a similar pattern of weight loss and recovery as SKO mice (Figure 3-13E). Since 
KLRG1+ CTLs enter the lung parenchyma during acute IAV infection (Figure 3-4), these results 
indicate that KLRG1+ TEFF cells may participate in viral clearance.   
Smad4 is not required for protection after recall 
Members of our laboratory previously examined heterosubtypic immunity in WT mice and 
demonstrated that pulmonary TRM cells are crucial for protection during the recall response, 
while nascent 2nd TEFF cells play very little role (61).  The protective effects of the TRM cells were 
evident from early viral clearance and reduced pathogenesis in the lungs (61). To analyze 
whether TGFβRII or Smad4 play a role in heterosubtypic immunity, separate groups of TKO, 
SKO and WT mice were infected with X31-OVA (H3N2 serotype) and weighed daily. and the 
mice were re-challenged 30 days later with WSN-OVA1 (H1N1 serotype). The order of infections 
was reversed for some experiments. Although the TKO mice underwent similar weight loss as 
WT mice during primary infection (Figure 3-13A), they recovered slightly slower than the WT 
group during the recall response (Figure 3-13C). This result was consistent with deficient 
development of CD103+ TRM cells in these mice. Additional mice will be analyzed for viral titers. 
In contrast the SKO and ST-DKO mice underwent more severe weight loss and recovered 
slower than WT mice during primary infection, but no deficit in protective immunity was 
observed during secondary infection (Figure 3-13D, Figure 3-13F). This result is consistent with 
normal TRM cell development in the SKO and STDKO mice and an important role in 
heterosubtypic immunity. 
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Discussion 
TGF-β is an important regulatory factor for peripheral CD8 T cells, which suppresses responses 
to self-antigens and prevents autoimmune disease (85). This cytokine also plays a critical role in 
cell-mediated immunity in mucosal tissues, where virus-specific CTLs use TGFβ-dependent 
adhesion molecules for local migration. A variety of signaling intermediates act downstream of 
the TGF-β receptor, including Smad2 and Smad3, which are chaperoned into the nucleus by 
Smad4 (87). This pathway is involved in differentiation of Th1 cells and production of IgA Abs 
(81;109), but it is not known to play a major role in CD8 T cell differentiation. In other situations 
Smad4 chaperones Smad1/5/8 into the nucleus after activation by the receptor for bone 
morphogenic proteins (BMPs); however, these pathways have not been fully analyzed in 
immune cells (110). Additional pathways that respond to the TGF-β receptor without involving 
Smad proteins use MAPKs, Rho-like GTPases, or PI3K as signaling intermediates leading to 
phosphorylation of Akt/S6/Foxo1/3a (76;80). At this time it is not clear which pathways support 
cell-mediated immunity and CD103 expression on pulmonary TRM cells. 
Our studies add an important piece to the puzzle by showing that Smad4 is not required for the 
development of CD103+CD69+ TRM cells in the lung, but is required for normal differentiation of 
multiple subsets of circulating CD8 T cells that use the bloodstream to move around the body. 
The Smad4-dependent subsets include KLRG1+ TEFF cells, which proliferate extensively in 
response to cytokine costimulation (29;51), as well as TCM cells which use CD62L to access 
resting lymph nodes between recurrent infections (55). Substantial numbers of Smad4-deficient 
CTLs survived the contraction of the TEFF cell response and lacked CD62L, but expressed 
CCR7 together with CD103, which are not characteristics of effector memory CD8 T cells. This 
phenotype likely explained why few Smad4-deficient CTLs were found in resting lymph nodes. 
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There are several potential explanations for the abnormal phenotype of the Smad4-deficient 
CD8 T cells: 1). It is possible that receptor-activated Smad2/3 proteins can function without 
Smad4; 2). TGFb signaling via Smad-independent signaling pathways may be enhanced in the 
absence of Smad4; 3). Smad4 may operate in other signaling pathways which do not require 
TGFb. Candidate ligands for the unknown pathway might include bone morphogenic proteins or 
activins. We were able to exclude the first two possibilities by generating CTLs that are deficient 
for both Smad4 and TGFβRII. The STDKO CTLs developed a similar phenotype as SKO CTLs 
during IAV infection, which confirms that Smad4 can regulate CD8 T cells independently of 
TGFβRII. This unknown pathway may be activated by an environmental signal that we refer to 
as “Smad4 ligand”. The reciprocal phenotypes of TKO and SKO CTLs may result from the 
competition for Smad4, or possible interactions between the TGFβ and Smad4 ligand pathways. 
Epithelial cells are an important site of viral replication and release large quantities of infectious 
virus into the lungs. Irreparable damage can occur when the virus reaches the alveoli and 
causes severe pulmonary effusion (111). Most TRM cells were embedded in the walls of the 
large airways, which is an ideal position for controlling viral replication. Although TGF-β plays a 
minor role in viral clearance during primary infection with mildly pathogenic strains of IAV, 
deficient generation of TRM cells in the absence of TGFβ had a more serious impact on 
heterosubtypic immunity, when pulmonary TRM cells provide frontline defenses in the lungs. On 
the other hand, KLRG1+ cells were dependent on Smad4, which could enter into the lung 
parenchyma during the acute phase of infection and may participate in viral clearance. 
Nevertheless, normal recovery of Smad4-deficient mice upon re-challenge confirmed that 
pulmonary TRM cells can reduce viral burdens with little assistance from nascent 2
nd TEFF cells 
generated from circulating memory cells.  
In summary, data in this chapter reveal a previously unknown role for Smad4 signaling in the 
regulation of effector and memory differentiation of CD8 T cells, which is independent of the 
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TGFβ receptor (Figure 3-14). Smad4 does not regulate the effector functions of CTLs, but is 
required for the terminal differentiation of KLRG-1+ TEFF cells, by a process that can be inhibited 
by TGFβ. Smad4 is dispensable for the TGFβ-mediated development of CD103+ TRM cells, 
which are crucial for protective immunity. We found that Smad4 suppresses aberrant CD103 
expression on CTLs in lymphoid organs, and is essential for the development of CD62L+ TCM 
cells, which were mostly absent from the resting lymph nodes when Smad4 was not expressed. 
Collectively, these findings provide important insights into the signals that control the distribution 
of virus-specific CTLs inside the lungs during IAV infection. 
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Figure 3-1. Anti-viral CTLs are regulated by TGF-β  
Chimeric mice were made with mixed bone marrow cells from TKO mice and WT littermates. 
Plots are representative of two independent experiments with n = 3-4/group.  
(A) Contour plots show CD44 and CD62L expression on CD8 T cells in peripheral blood of 
naïve mice 8 weeks after reconstitution. The histogram shows percentages of KLRG1+ within 
the CD8 gate. TKO (dashed line) and WT (gray fill) are shown.  
(B) Tetramer analysis was used to calculate the numbers of NP-specific CTLs in the lungs and 
spleens of chimeric mice after infection with X31-OVA. Donor cells from TKO mice (hatched) 
and wild type littermates (white). Mean ± SD, *p <0.05, ***p < 0.005.  
(C) Gated populations of NP-specific CTLs were analyzed for KLRG1 and CD103 expression. 
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Figure 3-2. TGF-β suppresses terminal differentiation of KLRG1+ TEFF cells by preventing 
prolonged cell proliferation 
Congenically marked OTI-WT and OTI-TKO cells were sorted for low CD44 expression and 
labeled with CFSE-dye before transfer to C57BL/6 recipients. The mice were infected with X31-
OVA and BrdU was injected on the days shown. Data are representative of 2 or 3 independent 
experiments (n = 3-4/group). 
(A) Bar graphs show the total numbers of transferred cells, including the KLRG1+ subset (gray 
shading). Mean ± SD. Statistical comparisons are shown in Table 3-1. 
(B) Overlaid histograms show CFSE-dilution 3.5 dpi. OTI-WT (gray fill), TKO (dashed line), and 
uninfected (solid line).  
(C) Transferred cells were analyzed 3 hrs (6 dpi) or 6 hrs (8 dpi and 10 dpi) after BrdU injection. 
Percentages of BrdU+ cells within gated populations of OTI-WT (white bars) and OTI-TKO 
(hatched bars). Mean ± SD. *p <0.05, ***p < 0.005.  
(D) Overlaid histograms show gated donor cells analyzed for activated caspase-3/7. OTI-WT 
(gray fill), OTI-TKO (dashed line), and unstained (solid line).  
(E) Gated populations of transferred cells were analyzed for Bcl2 expression. OTI-WT (gray fill), 
OTI-TKO (dashed line), and isotype control (solid line).  
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Figure 3-3. Pulmonary TRM cells require the TGFβ receptor for CD103 expression 
Congenically marked OTI-WT and OTI-TKO cells were sorted for low CD44 expression and 
transferred to C57BL/6 mice before X31-OVA infection (n = 3-4/group). Three independent 
experiments gave similar results. 
(A) CD103 and CD69 expression on donor cells in the lungs.  
(B) The total numbers of transferred cells were divided into subsets of CD69+ (hatched), 
CD69+CD103+ (black shading, TRM cells), CD103+ (gray shading), or no markers (white). Bars 
show means ± SD. Statistical comparisons are shown in Table 3-2. 
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Figure 3-4. KLRG1+ CTLs persist in the vasculature.  
(A) Congenically marked OTI-WT (top) or OTI-TKO (bottom) were sorted for low CD44 
expression and transferred to C57BL/6 mice before X31-OVA infection. Lung tissue was stained 
with antibodies to EpCAM to identify the large airways (red), CD31 for blood vessels (yellow), 
CD45.1 for transferred cells (blue), KLRG1 (green), and CD103 (magenta). Z-stack images 
were recorded at original magnification X20 (scale bars, 80 mm). Subregions show (I) 
colocalization between CD45.1 and KLRG1 or (II) colocalization between CD45.1 and CD103. 
Representative data from n = 3/group; two experiments gave similar results. 
(B) Lungs were harvested 30 dpi and transferred cells were analyzed for CD11a and KLRG1 
expression. Two experiments gave similar results (n=3-4/group).  
(C&D) OTI-WT and OTI-TKO were sorted for low CD44 expression and transferred to C57BL/6 
mice before X31-OVA infection. On the days indicated antibodies to CD8β were used for 
intravascular staining. Two experiments gave similar results (n = 3–4/group). 
(C) Gated populations of KLRG1+ CTLs were divided into CD8β+ (blood) and CD8β- (tissue 
resident) subsets.  
(D) After Intravascular staining the CD8β+ and CD8β- subsets were further analyzed for KLRG1 
and CD103 expression (left) or CD69 and CD103 expression (right) 40dpi.  
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Figure 3-5. CTLs have reciprocal phenotypes in the absence of TGF-βRII or Smad4 
Chimeric mice were made with mixed bone marrow cells from SKO mice and WT littermates.  
(A) Contour plots show CD8 T cells in peripheral blood of uninfected mice analyzed for CD44 
and CD62L expression. The histogram shows that KLRG1 was not expressed. SKO (dashed 
line) and WT (gray fill) are shown. Plots are representative of two independent experiments with 
n = 3–4 animals/group. 
(B) Chimeric mice were infected with X31-OVA and analyzed by MHCI tetramer analysis. Bar 
graphs show total numbers of NP-specific CTLs in the lungs and spleens. SKO (black) and 
littermates (white) are shown. Mean ± SD, *p <0.05, ***p < 0.005.  
(C) Gated populations of NP-specific CTLs were analyzed for KLRG1 and CD103 expression. 
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Figure 3-6. Smad4 is required for terminal differentiation of KLRG1+ TEFF cells 
Congenically marked OTI-WT and OTI-SKO cells were sorted for low CD44 expression and 
labeled with CFSE before transfer to C57BL/6 mice. 48hrs later the mice were infected withX31-
OVA infection. Some animals were injected with BrdU on the days shown. n = 3–4 
animals/group. Two or three independent experiments gave similar results. 
(A) Bar graphs show total number of transferred CTLs, including the KLRG1+ subset (gray 
shading). Means (± SD). Statistical comparisons are shown in Table 3-1. 
(B) Donor cells were analyzed for CFSE dilution 3.5 dpi. OTI-WT (gray fill), SKO (dashed line), 
and uninfected (solid line).  
(C) Percentages of BrdU+ cells within gated populations of OTI-WT (white bars) and OTI-SKO 
(black bars). Means ± SD, *p <0.05, ***p < 0.005.  
(D) Overlaid histograms show gated donor cells analyzed for activated caspase-3/7. OTI-WT 
(gray fill), OTI-SKO (dashed line), and unstained (solid line).  
(E) Gated populations of transferred cells were analyzed for Bcl2 expression. OTI-WT (gray fill), 
OTI-SKO (dashed line), and isotype control (solid line).  
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Figure 3-7. Pulmonary TRM cells form in the absence of Smad4. 
Congenically marked OTI-WT and OTI-SKO cells were sorted for low CD44 expression and 
transferred to C57BL/6 mice before X31-OVA infection. (n = 3–4 animals/group). Three 
independent experiments gave similar results 
(A) CD103 and CD69 expression on donor cells in the lungs.  
(B) Total numbers of transferred CTLs were subdivided into subsets of CD69+ (hatched), 
CD69+CD103+ (black shading = TRM cells), CD103+ (gray shading), or no markers (white). 
Means ± SD. Statistical comparisons are shown in Table 3-2. 
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Figure 3-8. Smad4-deficient CTLs are widely distributed inside the lungs. 
Congenically marked OTI-WT (top) or OTI-SKO cells (bottom) were sorted for low CD44 
expression and transferred to C57BL/6 mice before X31-OVA infection.  
(A) Lung tissue was stained with antibodies to EpCAM to identify the large airways  (red), CD31 
for blood vessels (yellow), CD45.1 for transferred cells (blue), KLRG1 (green), and CD103 
(magenta). Z-stack images were recorded at original magnification X20 (scale bars, 80 mm). 
The subregions show (I) colocalization between CD45.1 and KLRG1 or (II) colocalization 
between CD45.1 and CD103. Representative images from n=3/group. Two experiments gave 
similar results. 
(B) Lungs were harvested 30 dpi and gated populations of OTI-SKO and OTI-WT cells were 
analyzed for CD11a and KLRG1 expression; n=3-4/group. Two experiments gave similar results.  
(C-E) Intravascular staining was used to identify CTLs that were circulating in the blood stream. 
The transferred cells were divided into CD8β+ and CD8β- subsets and analyzed for KLRG1 and 
CD103 expression in (C) lungs and (D) spleens or (E) CD69 and CD103 expression in lungs. 
Representative data are from n = 3-4/group. Two experiments gave similar results. 
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Figure 3-9. Smad4 is required for CD62L expression and entry into resting lymph nodes  
Congenically marked OTI-WT, OTI-TKO, and OTI-SKO cells were sorted for low CD44 
expression and transferred to C57BL/6 mice before X31-OVA infection. Representative data 
from n=3-4/group. Two experiments gave similar results. 
(A) CD62L and CD103 expression on gated OTI-WT, OTI-TKO, and OTI-SKO cells 30 dpi. Dot 
plots show representative data from 3-4 animals per group. Three independent experiments 
gave similar results.  
(B) Numbers of CD62L+ TCM (black), CD62L- (white), CD62L+CD103+ (hatched), and CD62L-
CD103+ transition (gray fill) cells 30 dpi. Mean ± SD. Statistical comparisons are shown in 
Table 3-3.  
(C) Overlaid histograms show CCR7 expression on OTI-WT (gray fill), OTI-SKO or OTI-TKO 
(dashed line), and isotype control (solid line).  
(D) Mean fluorescence intensity for CCR7 staining. OTI-TKO (hatched), SKO (black), and 
littermates (white). *p < 0.05. 
(E) Inguinal lymph nodes were imaged 20 dpi. CD31 (yellow), CD45.1 (blue), B220 (red), 
CD103 (magenta). (I-II) Subregions (white boxes) show enlarged images of transferred CTLs, 
with the total numbers of cells in the field (means ± SD; n=3). Z-stack images were recorded at 
original magnification 310.  
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Figure 3-10. The Smad4-deficient CTLs are not regulated by the TGFβ receptor. 
Congenically marked OTI-WT and OTI ST-DKO cells were sorted for low CD44 expression and 
transferred to C57BL/6 mice before X31-OVA infection. Data are representative of n=4/group. 
(A) Numbers of KLRG1+ CTLs (gray shading) and KLRG1- CTLs (white) among donor 
populations. Mean ± SD.  
(B) Donor cells were labeled with CFSE-dye and transferred to recipient mice 48 hrs before IAV 
infection. OTI-WT (Gray fill) and OTI ST-DKO (dashed line) cells were analyzed for CFSE 
dilution 3.5 dpi (n=4/group), with donor cells in uninfected recipients as control (solid line). 
(C) BrdU was injected on the days shown, and donor cells were analyzed between 3 and 6 h 
later. Percentages of BrdU+ cells within gated populations of OTI-WT (white bars) and OTI ST-
DKO cells (grey bars). Means ± SD.  
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Figure 3-11. Smad4 acts as a suppressor of CD103 expression 
OTI-WT, OTI-SKO, and OTI ST-DKO cells were sorted for low CD44 expression and transferred 
to C57BL/6 mice 48 h before infection with X31-OVA. Data were representative of n=4/group. 
(A) Kinetics of CD103 expression on OTI-WT (grey shade), OTI-SKO (dashed line, top) and OTI 
ST-DKO (dotted line, bottom) cells.  
(B) Bar graphs show total numbers of transferred cells, including subsets of CD69+ (hatched), 
CD69+CD103+ (black shading, TRM cells), CD103+ (gray shading), or no markers (white). 
Means ± SD. 
(C) CD62L and CD103 expression on gated OTI-WT and OTI ST-DKO cells 30 dpi. Bar graphs 
show mean fluorescence intensity for CCR7 staining on OTI-WT (white) and OTI ST-DKO(black) 
cells. 
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Figure 3-12. TGFβ or Smad4 did not alter cytokine production of CTLs 
Congenically marked OTI-WT, OTI-TKO and OTI-SKO cells were sorted for low CD44 
expression and transferred to C57BL/6 mice before X31-OVA infection. Lymphocytes were 
isolated from the lungs 40 dpi and stimulated with SIINFEKL peptide for 5 hrs in the presence of 
Brefeldin A. Numbers show percentages of donor cells producing IFNγ and TNFα within the 
KLRG1 and CD103 subsets. Two experiments gave similar results with n=3-4/group. 
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Figure 3-13. Smad4 is required for viral clearance during primary infection but not 
heterosubtypic immunity 
Genetically-modified mice and wild type litter mates were given a sublethal dose of IAV 
intranasally (i.n.) and weighed daily. 30 dpi after primary infection groups of mice were re-
challenged with a heterosubtypic strain of IAV i.n. and weighed daily. The graphs show 
reduction in body weight as percentage of starting weight. Combined data from two independent 
experiments are shown. *p <0.05, **p < 0.01. 
(A&B) Weight loss during primary infection with X31-OVA (103pfu).  
(A) TKO = open circle (n=7), littermate controls = black circle (n=6). 
(B) SKO = open square (n=9), littermate controls = black square (n=6)  
(C&D) Weight loss during Secondary infection. Mice were primed with X31-OVA (103pfu) and 
challenged 30dpi with WSN-OVA1 (5x103pfu). Naive mice were primed with WSN-OVA1 
(5000pfu) as controls. 
(C) TKO = open circle (n=2), littermate controls = black circle (n=3). Unprimed control = grey 
square (n =7). 
(D) SKO = open square (n=4), littermate controls = black square (n=4). Unprimed control = grey 
square (n =7). 
(E&F) Weight loss by mice lacking both TGFβ receptor and Smad4 (STDKO). Mice were primed 
with WSN-OVA1 (103pfu) and challenged 30dpi with X31-OVA (5x103pfu).  
(E) Weight loss during primary infection. ST-DKO = open triangle (n=6), littermate controls = 
black triangle (n =8).  
(F) Weight loss during secondary infection. ST-DKO = open triangle (n=4), littermate controls = 
black triangle (n=8). Naïve mice were infected with 5000pfu X31-OVA as control. Unprimed = 
grey square (n =4). 
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Figure 3-14. Model illustrating the roles of Smad4 and TGFβ during the differentiation of 
virus-specific CTLs. 
Left panel, Normal CD8 T cells give rise to mixed populations KLRG1+ TEFF cells, CD103+ TRM 
cells, and circulating memory CD8 T cells. Middle panel, TGF-β signaling reduces the numbers 
of terminally differentiated TEFF cells and is essential for TRM development. Right panel, Smad4 
dependent signaling is required for terminal differentiation of virus-specific TEFF cells and TCM 
cells. 
  
KLRG1+ KLRG1-
6d *** ns
8d ** ns
10d * ns
15d * ns
30d *** ns
KLRG1+ KLRG1-
6d * ns
8d * ns
10d *** *
15d *** ns
30d *** ns
KLRG1+ KLRG1-
6d *** ns
8d *** **
10d ** ns
15d *** ns
30d *** ns
MLNs Spleens Lungs
OTI-TKO vs. OTI-WT
Table 3-1
Table 3-1. Statistical comparisons for Figure 3-2.  
An unpaired two-tailed Student’s t test was used to compare the numbers of OTI-WT and OTI-
TKO after transfer and IAV infection based on expression of KLRG1 (ns = not significant;* P < 
0.05; ** P <0.01; *** P < 0.005). Red lettering indicates larger numbers of mutant CTLs and blue 
lettering indicates larger numbers of WT CTLs. 
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Table 3-2
Table 3-2. Statistical comparisons for Figure 3-3.  
An unpaired two-tailed Student’s t test was used to compare the numbers of OTI-WT and OTI-
TKO after transfer and IAV infection based on expression of CD69 and CD103 (ns = not 
significant;* P < 0.05; ** P <0.01; *** P < 0.005). Red lettering indicates larger numbers of 
mutant CTLs and blue lettering indicates larger numbers of WT CTLs. 
65
KLRG1+ KLRG1-
6d ns ns
8d ns ns
10d ns ns
15d ns ns
30d ns ns
KLRG1+ KLRG1-
6d ** ns
8d ns ns
10d * ns
15d ns ns
30d *** ns
KLRG1+ KLRG1-
6d ns ns
8d * ns
10d * ns
15d * ns
30d *** ns
MLNs Spleens Lungs
OTI-SKO vs. OTI-WT
Table 3-3. Statistical comparisons for Figure 3-6   
An unpaired two-tailed Student’s t test was used to compare the numbers of OTI-WT and OTI-
TKO after transfer and IAV infection based on expression of KLRG1 (ns = not significant;* P < 
0.05; ** P <0.01; *** P < 0.005). Red lettering indicates larger numbers of mutant CTLs and blue 
lettering indicates larger numbers of WT CTLs. 
Table 3-3
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Table 3-4. Statistical comparisons for Figure 3-7.  
An unpaired two-tailed Student’s t test was used to compare the numbers of OTI-WT and OTI-
SKO after transfer and IAV infection based on expression of CD69 and CD103 (ns = not 
significant;* P < 0.05; ** P <0.01; *** P < 0.005). Red lettering indicates larger numbers of 
mutant CTLs and blue lettering indicates larger numbers of WT CTLs. 
Table 3-4
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Table 3-5
Table 3-5. Statistical comparisons for Figure 3-9.  
An unpaired two-tailed Student’s t test was used to compare the numbers of transferred OTI-WT, 
OTI-TKO and OTI-SKO cells after X31-OVA infection based on expression of CD103 and 
CD62L (ns = not significant;* P < 0.05; ** P <0.01; *** P < 0.005). Red lettering indicates larger 
numbers of mutant CTLs and blue lettering indicates larger numbers of WT CTLs. 
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CHAPTER IV 
MECHANISMS OF SMAD4 SIGNALING IN CD8 T CELLS 
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Abstract 
The data in the previous chapter show that Smad4 can regulate differentiation of effector and 
memory CD8 T cells independently of the TGFβ receptor. To further define the signaling 
pathways, and downstream target genes, we compared the global transcriptional profile of wild 
type and Smad4-deficient CTLs during IAV infection, using RNA-sequencing and bioinformatics 
for comparative analysis. The data show that Smad4-deficiency caused major changes in the 
transcriptional program of early TEFF (EE) cells, including dysregulated expression of several 
genes that are involved in cell migration and proliferation. In chapter III we showed that late 
proliferation and terminal differentiation of TEFF cell were suppressed by TGFβ, but were 
dependent on Smad4. Since cell proliferation is linked to increased energetic demands, we use 
a Seahorse flux analyzer to compare cellular metabolism in mutant and wild type CTLs during 
IAV infection.  Ex vivo analysis showed that CTLs lacking the TGFβ receptor were capable of 
prolonged glycolysis during the TEFF response. However this effect was not seen in EE cells 
lacking Smad4, which showed signs of enhanced mitochondrial biogenesis. Previous studies 
have shown that pro-inflammatory cytokines provide a third signal during CD8 T cell 
differentiation and promote terminal differentiation of TEFF cells. The RNA-sequencing suggested 
that CTLs lacking Smad4 express the IL-12 receptor at reduced levels, and we found that the 
cells did not signal via STAT4 efficiently during in vitro stimulation with recombinant cytokine. 
We also found that the transcriptional regulator Eomesodermin was expressed at reduced levels 
in the Smad4-deficient cells, whereas CTLs lacking the TGFβ receptor expressed 
Eomesodermin at high levels. Together these data indicate that regulation of the CTL response 
via Smad4 involves a cooperative response with IL-12 and some T-box transcription factors. 
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Introduction 
Our results in Chapter 3 demonstrate that Smad4 deletion led to significantly altered effector 
and memory CD8 T cell differentiation independently of the TGFβ receptor. CD8 T cell 
responses are mainly governed by signaling from the T cell receptor (TCR) (signal 1), co-
stimulatory molecules (signal 2) and pro inflammatory cytokines (signal 3) (112). All three 
signals are present during infection in vivo, and antigen-specific CTLs integrate the strength and 
duration of these signals to regulate their transcriptional profiles. We previously showed that 
deletion of TGFβRII, but not Smad4, led to late proliferation and terminal differentiation of TEFF 
cells (51). Since cell proliferation is usually supported by increased metabolism (113;114), we 
used RNA-sequencing to investigate whether TGFβ or Smad4 regulate the expression levels of 
genes that are involved in cellular metabolism and migration. 
Major metabolic changes during T cell activation. 
The metabolic requirements of CD8 T cells change during the response to infection and reflect 
remodeling of diverse metabolic pathways (Figure 4-1). Naïve CD8 T cells rely on fatty acid 
oxidation (FAO), or oxidative phosphorylation (OXPHOS) of glucose-derived pyruvate in the 
mitochondria for energy generation. This process begins in the cytosol, when glucose is 
converted to pyruvate (Figure 4-1, Green box) and enters the mitochondria. In resting cells, 
pyruvate is converted to acetyl coenzyme A (CoA) and oxidized in the tricarboxylic acid (TCA) 
cycle to generate NADPH, which fuels ATP production via the electron transport chain (Figure 
4-1, yellow box)(115). Upon activation, CTLs switch to aerobic glycolysis when glucose is 
fermented into lactate despite the presence of sufficient oxygen (116). Glycolysis only produces 
2 molecules of adenosine triphosphate (ATP) per glucose, while 36 molecules of ATP are 
generated from one molecule of glucose by OXPHOS. This switch is required to generate the 
metabolic intermediates that are used to increase biomass during cell proliferation and cytokine 
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production, and also helps maintain the redox (NAD+/NADH) balance in activated CTLs (117). 
Glycolysis produces glycose-6-phosphate, which supports nucleotide synthesis via the pentose 
phosphate pathway, and 3-phosphoglycerate (3-PG) which can serve as the substrate for serine 
biosynthesis (116;117). Resting cells use the TCA cycle to convert acetyl-CoA and oxaloacetate 
to citrate and generate substrates for the electron transport chain. In contrast, activated cells 
shuttle citrate back to the cytosol, where it is converted back Acetyl-CoA and used as a 
substrate for de novo lipid synthesis (Figure 4-1, blue box). Acetyl-CoA carboxylase (ACCs) 
catalyzes the first step of fatty acid synthesis (FAS) to generate malonyl-CoA, which is a potent 
suppressor of FAO (118;119). Recent studies have shown that T cells can adapt to low 
availability of glucose by using glutamine for OXPHOS in the mitochondria (120). While TEFF 
cells survive and proliferate in the absence of glucose, cytokine expression is critically 
dependent on the availability of glucose and anabolic metabolism (117;120). After the 
contraction of the TEFF response, memory CD8 T cells switch back to OXPHOS (121;122). 
Unlike naïve T cells which are metabolically quiescent and TEFF cells which are metabolically 
active, memory CD8 T cells are considered to be “metabolically primed” (114). Memory cells 
have enhanced mitochondria mass and increased spare respiratory capacity, which not only 
supports long-term survival but also provides a bioenergetic advantage for rapid ATP production 
upon re-exposure to antigen (123;124). Interestingly, memory T cells retain the machinery for 
glycolysis and lipid synthesis, which are is not present in naïve CD8 T cells. A recent study 
showed that memory CD8 T cells cannot adsorb free fatty acids very efficiently, and thus use 
extracellular glucose to fuel FAO and OXPHOS. During this process lipids are synthesized by 
lysosomal acid lipase (LAL)-mediated lipolysis of triglyceride (TAG) (124). The glycerol channel 
aquaporin 9 (AOP 9), which is induced by IL-7, is required for glycerol import into memory CD8 
T cells and subsequent synthesis of TAG (125). 
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Signaling pathways that regulate T cell metabolism 
The metabolic profiles of antigen-specific CD8 T cells are regulated by environmental signals 
during infection (126). Early after activation, the metabolic switch to enhanced glycolysis is 
mediated by signals from the TCR, costimulation via CD28 and growth factors such as IL-2 or 
other pro-inflammatory cytokines. These signals upregulate c-Myc expression and stabilize 
hypoxia-induced factor 1α (HIF-1α), which are key regulators of the glycolytic switch (116;127). 
These signals also significantly enhance the activity of mammalian target of rapamycin (mTOR) 
complexes via the PI3K/Akt pathway, which plays a key role in differentiation of TEFF cells. 
Studies have shown that inhibiting mTOR using rapamycin, or activating AMPK with metformin, 
enhances the generation of memory CD8 T cells (128;129). On the other hand, deficiencies in 
TSC1/2 (upstream inhibitor of mTOR), LKB1 (upstream activator of AMPK) or AMPKα1 leads to 
sustained glycolytic activity and defective development of memory cells (130-132).  During 
memory generation, AMP-activated protein kinase (AMPK) is activated in response to 
decreased cellular energy (i.e. increased AMP/ATP ratio), to promote FAO and suppress 
glycolysis (132), while IL-15 is essential for the homeostasis of memory CD8 T cells and 
enhanced mitochondrial biogenesis (123).  
Transcriptional control of CD8 T cell differentiation 
Environmental signals govern the expression levels of several key transcription factors that 
determine the fate of TEFF cells (112;133). Some pairs of transcription factors function in a 
reciprocal way during CD8 T cell differentiation. Examples include the T-box transcription factor 
T-bet, which  coordinates its actions with the downstream transcription factor Zeb2 (134;135) 
thus creating a gradient effect on the numbers of terminally-differentiated TEFF cells (29). T-bet is 
positively regulated by pro-inflammatory cytokines such as IL-12, which links inflammation with 
expansion and terminal differentiation (28). In contrast, Eomesodermin (Eomes), which is 
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homologous to T-bet in the DNA-binding domain, facilitates long-term persistence of memory T 
cells (136). Another example of a counter-regulatory pathway involves B lymphocyte-induced 
maturation protein-1 (Blimp-1) and B-cell lymphoma 6 (Bcl-6). Blimp-1 expression is induced by 
IL-2 and represses the expression of Bcl-6, thereby promoting effector functions and memory 
formation (137;138). In addition, two inhibitors of DNA binding proteins (Id2 and Id3) work 
together, since high expression of Id3 in EE cells preferentially induces long-lived memory cells, 
while Id2 promotes the survival of terminally differentiated TEFF cells (139). Reciprocal regulation 
can also occur via STAT3 and STAT4, which promote distinct TEFF cell fates. STAT4 activity is 
induced by IL-12 and/or type I IFN, to increase T-bet expression and terminal differentiation of 
TEFF cells (140). In contrast, STAT3 is activated by IL-10 and/or IL-21 to promote memory T cell 
development by inducing Bcl6, Eomes and the suppressor of cytokine signaling 3 (SOCS3), 
which in turn dampen the response to IL-12 (141). Meta-analyses of gene-expression profiles 
demonstrate that the cell-fate decisions of TEFF cells are controlled by a complex transcriptional 
network, rather than a single ‘master regulator’ (142;143). Since our data show that the 
formation of KLRG1+ TEFF cells is reciprocally governed by TGFβ and Smad4, we further 
examined whether deletion of Smad4 interfered with the pathways that regulate key 
transcription factors. 
Major goals for chapter 4: 
Aim 2.1 To identify transcriptional targets of Smad4 signaling in activated CTLs 
Aim 2.2 To examine whether Smad4 is involved in regulation of cellular metabolism after CD8 T 
cell activation 
Aim 2.3 To determine whether Smad4 regulates the CTL response to IL-12. 
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Results  
Transcriptional profiles regulated by Smad4 
Our results in chapter 3 suggest that Smad4 plays a previously unappreciated role in regulation 
of the CD8 T cell response, which is independent of TGFβ. Therefore we analyzed the gene 
profiles of activated OTI-WT and OTI-SKO cells by RNA-sequencing to identify the transcription 
program that is regulated by Smad4. Equal numbers of OTI-WT and OTI-SKO cells were 
transferred into recipient mice 48h before X31-OVA infection as in our previous experiments. 
The transferred cells were sorted from the spleens 6dpi for RNA-sequencing (RNA-Seq), a time 
point when the majority of the OTI-WT and OTI-SKO cells maintained an early effector 
phenotype (KLRG1loCD127loCD103loCD44hi) (Figure 4-2).  
RNA-Seq identified 197 genes with differential expression levels of greater that 2-fold between 
the OTI-SKO and OTI-WT cells (Figure 4-3, Table 4-1). Among these genes 138 genes were 
upregulated in absence of Smad4 (red) and 59 genes were downregulated (blue). The Ingenuity 
pathway analysis (IPA) is web-based software that is used for the analysis and interpretation of 
RNA-Seq data based on the manually curated Ingenuity Knowledge Database 
(http://www.ingenuity.com/products/ipa). IPA was used to analyze the genes with significantly 
different expression levels in our RNA-Seq, and showed that 78 genes were associated with 
‘cellular movement’ (Figure 4-4A). These dysregulated genes included adhesion molecules 
such as integrins and chemokine receptors (Figure 4-4B). As expected, transcription of the Itgae 
gene which encodes CD103 was highly upregulated in the absence of Smad4 (log2=4.18), even 
though the donor cells were sorted for low CD103 expression early in the response. In contrast, 
transcription of the Sell gene (CD62L) was down-regulated in the OTI-SKO cells by 6dpi (log2=-
1.26).  
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IPA also identified significant changes in the transcription levels of 77 genes that are involved in 
‘Cell Growth and Proliferation’ as well as 84 genes that are involved in ‘Cell Death and Survival’ 
including many genes that are involved in signaling downstream of costimulatory molecules 
(signal 2) and cytokines (signal 3) which are known to play important roles in the proliferation 
and survival of TEFF cells during infection (Figure 4-4A, Figure 4-4B). The IL-7 receptor (Il7r or 
CD127) was up-regulated in EE cells from OTI-SKO mice (log2=1.15), which is consistent with 
preferential formation of memory precursors. On the other hand a subunit of the high affinity IL-
12 receptor (Il12rb2) was downregulated in the OTI-SKO cells (log2=-1.12). Although studies 
have shown that IL-12 signaling promotes terminal differentiation of KLRG1+ TEFF cells by 
inducing the expression of the transcription factor T-bet (29), there was very little difference in 
the transcription levels of T-bet in Smad4-deficient CTLs during IAV infection. In contrast the 
ligand for CD40 (cd40lg) was transcribed at reduced levels in the OTI-SKO cells (log2=-1.09). 
While CD40L is mostly known for its role in CD4 T cell-mediated help (144); expression is 
upregulated in activated CD8 T cells and thus promotes IL-12 production from CD8α+ DCs 
(145). Although our RNA-Seq did not reveal a significant difference in Klrg1 transcription, a 
related gene (Klre1) which has no known function was significantly downregulated in the OTI-
SKO cells (log2= -1.05). The literature also shows low expression of this gene in memory 
precursors, relative to terminally differentiated TEFF cells (29).  
Our RNA-Seq identified changes in the expression levels of multiple transcription factors which 
are known to regulate the CD8 T cell response (Figure 4-4B). A recent study showed that 
downregulation of Eomes is essential for the development of CD103+ TRM cells in the skin (146). 
In another study downregulation of Eomes led to increased expression of the TGFβ receptor, 
while TGFβ signaling can suppress Eomes expression (146). Furthermore, deletion of Eomes 
resulted in diminished numbers of TCM cells (147). We found that Eomes was significantly 
downregulated in the OTI-SKO cells (log2= -1.67), which was consistent with widespread 
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CD103 expression and deficient development of CD62L+ TCM cells. Other genes that were 
highly expressed in the OTI-SKO cells included the Ahr gene (log2= 1.81) which encodes the 
ligand for the aryl hydrocarbon receptor (AHR). This pathway is involved in the maintenance of 
skin TRM cells, as well as skin and intestinal γδ T cells (40;41).  
Together the transcriptional changes that were observed in the absence of Smad4 suggest that 
anti-viral CTLs acquire a transcriptional signature of TRM cells during an early phase of the CTL 
response to IAV infection. We used gene set enrichment analysis (GSEA) to compare data sets 
from the literature with the transcriptional changes identified in our RNA-Seq. The reference 
data set was comprised of genes that were upregulated more than 4-fold in TRM cells that were 
isolated from the lungs during IAV infection, relative to TCM cells isolated from the spleens of 
HSV infected mice (62). A comparison between this reference set and our RNA-seq data, 
showed significant enrichment for the transcriptional profile of OTI-SKO cells (Figure 4-4C). A 
core signature for TRM cells was recently identified by comparing the transcripts in TRM cells from 
the skin, gut and lungs with TCM and TEM cells in the spleens (62). Many of the genes that were 
identified in this study were also dysregulated in our RNA-seq, including Itgae and Eomes 
(Figure 4-4D). Since the EE cells from Smad4 KO mice were transcriptionally programmed 
towards TRM cell development, we postulate that Smad4 regulates memory CD8 T cell 
differentiation during an early stage of the CTL response. 
Smad4 regulates the transcription of genes involved in cellular metabolism 
Data from autoimmunity and tumor models indicate that Smad4 has a TGFβ receptor-
independent role in promoting T cell proliferation by directly regulating c-Myc expression and 
DNA binding (148). Our RNA-Seq data showed that c-Myc was significantly downregulated in 
the absence of Smad4 (log2=-1.23) (Figure 4-4B). In contrast, the myc oncogene is  highly 
expressed in many types of tumor cells and is upregulated in TEFF cells from normal mice, 
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causing metabolic reprogramming toward increased glycolysis and glutaminolysis (116). 
Conditional deletion of c-Myc from TEFF cells abrogated cell growth and proliferation after 
antigen stimulation (116). The Tfap4 gene encodes activating enhancer binding protein 4 (AP4), 
which is a the transcription factor that acts downstream of c-Myc and drives clonal expansion of 
antigen-specific CTLs (149). Our data showed significantly lower mRNA transcription of Tfap4 
(log2=-1.04) in OTI-SKO cells (Figure 4-4B). Since the RNA-seq data showed low levels of c-
Myc and AP4 expression in Smad4-deficient cells, we used using Gene Set Enrichment 
Analysis (GSEA) to other dysregulated genes in OTI-SKO cells with the transcriptional signature 
of in vitro activated CD8 T cells after conditional deletion of c-Myc (149). This study showed that 
many genes which were upregulated more than 4-fold in c-Myc-deficient CD8 T cells (146), 
were also significantly enriched in the OTI-SKO cells, relative to OTI-WT cells (Figure 4-5A). 
Relevant to this thesis, the Itgae gene (CD103) was the most upregulated gene in the c-Myc-
deficient CTLs, as compared to WT cells (149).  
Considering the important role of c-Myc in metabolic reprogramming during T cell activation 
(112), we examined the RNA-seq data for dysregulation of genes that are involved in cellular 
metabolism (Figure 4-5B). We found that the gene for the peroxisome proliferator-activated 
receptor gamma (PPARγ), which is a key regulator of lipid metabolism and glucose 
homeostasis (150), was upregulated (log2=1.66) in the OTI-SKO cells. In addition, Nr1h3 
(log2=1.15) which encodes the liver X receptor α chain (LXRα) and is involved in cholesterol 
transport was upregulated. In normal cells, expression of Nr1h3 is suppressed during T cell 
activation to favor of cholesterol synthesis (151). We also found that Slc2a3, which encodes the 
glucose transporter Glut3, was downregulated in OTI-SKO cells (log2=-0.84), while Glut1 was 
expressed at normal levels. Similarly Pdk1 which encodes pyruvate dehydrogenase kinase 1 
(PDHK1), was downregulated (log2=-0.79). PDHK1 plays a key role in CD4 T cell differentiation 
by inhibiting the activity of pyruvate dehydrogenases and therefore controls glucose entry into 
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the TCA cycle (152). Finally, transcription of fatty acid synthase (Fasn), a key enzyme of fatty 
acid synthesis, was moderately downregulated in OTI-SKO cells (log2=-0.72). Together these 
results support the hypothesis that Smad4 deletion alters the metabolic profile of anti-viral CTLs 
during the TEFF response. 
TGFβ may regulate shift from glycolysis to OXPHOS in memory precursors 
Extensive research has shown that cell proliferation requires increased energy for biosynthesis 
of membrane components and cellular organelles (122). As TGFβRII and Smad4 differentially 
regulate late proliferation in TEFF cells, we further examined the mutant CTLs for defects in 
cellular metabolism using a Seahorse® flux analyzer (150).  
For this study EE cells (KLRG1loCD127lo) were purified from the spleens of IAV infected mice at 
various time points after infections and memory precursors (MPECs, KLRG1loCD127hi) were 
isolated 8dpi. The purified cells were plated in 96 well plates and a glycolysis Stress Test® was 
used to examine their glycolytic capacity directly ex vivo (153). During glycolysis cells extrude 
protons causing acidification of the culture media, which can be measured as extracellular 
acidification rate (ECAR). Glucose was injected at the beginning of the test to increase ECAR  
and establish a baseline for glycolysis under resting conditions. Next Oligomycin treatment was 
used to inhibit ATP synthesis in the mitochondria, which leads to a further increase in ECAR as 
the cells accelerate ATP production. The ECAR measured under ‘stress conditions’ indicates 
the maximum glycolytic capacity of the cells, while the difference between the maximal and 
basal ECAR is used to define the glycolytic reserve of the cells. At the end of the test, 2-DG is 
used to shut down glycolysis by inhibiting hexokinase activity, thereby causing a significant 
decrease in ECAR. 
The glycolysis Stress Test did not reveal any significant differences in the glycolysis rate of EE 
cells isolated from OTI-WT and OTI-TKO mice during the expansion (3.5 and 6dpi) or the peak 
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of the TEFF response (8dpi) (Figure 4-6A). In contrast, memory precursors that lacked the TGFβ 
receptor showed significantly higher ECAR under both basal and stress conditions than WT 
cells and maintained a higher glycolytic reserve 8dpi (Figure 4-6B), which is consistent with their 
capacity for prolonged proliferation, as shown in chapter III. In contrast, Smad4 deficiency did 
not alter the glycolytic capacity of TEFF cells at any time point (Figure 4-6). These data suggest 
that TGFβ may regulate the switch from glycolysis back to OXPHOS during the transition to 
memory formation.  
TGFβ and Smad4 may reciprocally regulate mitochondrial respiration 
We next performed a Mito Stress Test® to evaluate OXPHOS in TEFF cells lacking the TGFβ 
receptor or Smad4. For this test basal oxygen consumption rate (OCR) is used to measure 
OXPHOS activity in mitochondria under resting conditions. After treatment with Oligomycin a 
decrease in OCR reflects the mitochondrial respiration that is associated with ATP production. 
Maximal OCR is determined using Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone 
(FCCP) to disrupts the mitochondrial membrane potential and stimulate the electron transport 
chain (ETC) to operate at maximum capacity. The increase from basal OCR to maximal OCR is 
defined as spare respiratory capacity (SRC). High SRC is associated with enhanced cell 
survival and persistence, which are determined by substrate delivery to the mitochondria, as 
well as the activity of the enzymes associated with OXPHOS (154). A third injection of Rotenone 
and Antimycin inhibits Complex I and Complex III activities in the ETC and shuts down 
OXPOHOS in mitochondria. The remaining OCR is a result of non-mitochondrial respiration.  
There was no difference in the basal respiration for EE cells from OTI-WT and OTI-TKO mice 
during IAV infection (Figure 4-7A, Figure 4-8). However the maximal OCR and SRCs were 
decreased 3.5dpi (Figure 4-8). As SRC is important for CD8 T cell memory development (123), 
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the TGFβ receptor may use this pathway to impair memory formation and favor the generation 
of KLRG1+ TEFF cells. 
In similar experiments, EE cells from OTI-SKO mice displayed significantly higher basal and 
maximal OCRs than wild type cells (Figure 4-7A, Figure 4-8), which could indicate enhanced 
mitochondrial biogenesis and preferential use of OXPHOS for energy production. Analysis of EE 
cells during the expansion phase of the TEFF response (6dpi) did not reveal any difference in 
energy consumption. The maximal OCR for EE cells that were isolated at the peak of the CTL 
response (8dpi) was slightly higher for the OTI-SKO than WT cells, which may indicate faster 
conversion from glycolysis back to OXPHOS. Smad4-deletion did not significantly affect the 
SRC of the CTLs, which indicates that Smad4 deletion did not alter substrate delivery and 
enzyme activity in mitochondria under stressed condition (Figure 4-8). Overall the data indicate 
that Smad4 may suppress mitochondria biogenesis after T cell activation. 
TGFβ or Smad4 deletion does not alter mitochondrial fuel usage 
Glucose, fatty acids, and amino acids can all be used as substrates for OXPHOS in the 
mitochondria. Recent studies showed that SRC in memory CD8 T cells is fueled by fatty acid 
oxidation (FAO) (123;124). To examine whether TEFF cells from OTI-TKO or OTI-SKO mice rely 
on FAO for SRC, we performed a Mito stress test® in the presence of Etomoxir to inhibit 
carnitine palmitoyl transferase 1α (CPT1α) activity, which is the rate-limiting enzyme for FAO 
(155). During this assay inhibition of FAO abrogated the SRC and decreased the OCR to basal 
levels in both wild type and mutant cells (Figure 4-9A). Treatment with Etomoxir also decreased 
the basal OCR regardless of whether the cells expressed the TGFβ receptor or Smad4 (Figure 
4-9B). Therefore use of FAO to fuel OXPHOS during both basal and stress states was not 
altered by TGFβRII or Smad4 deletion. 
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We used another inhibitor, BPTES, to shut down glutamine oxidation in the mitochondria by 
inhibiting glutaminase GLS1 activity (156). This inhibitor did not affect either the basal or 
maximal OCRs of TEFF cells (Figure 4-9B). It is possible that other glutaminases compensate for 
inhibition of GLS1, as glutamine depletion in media decreased the OCR and OCR/ECAR ratios 
for all three cell types under basal conditions (Figure 4-9C). These results are consistent with 
the role of glutaminolysis in fueling OXPHOS in TEFF cells (120). 
Lastly, UK5099 blocks the transport of glucose-derived pyruvate into the mitochondria (157). 
This inhibitor had no impact on the basal OCR and abrogated the SRC for all three types of 
cells (Figure 4-9B). Consistently, the literature shows that memory CD8 T cells generated in 
vitro are depend on extracellular glucose to support FAO through intrinsic lipid synthesis and 
lipolysis (124). We found that deprivation of glucose during cell culture resulted in a higher ratio 
of OCR/ECAR ratio for all three types of cells (Figure 4-9C). Consistently, a recent study 
showed that AMPK pathway can upregulate glutamine oxidation in TEFF cells in response to low 
glucose availability (120). In summary, ex-vivo analysis of TEFF cells showed that all three types 
of cells were able to adapt to different substrates for OXPHOS, which suggests that these 
processes are not regulated by TGFβRII or Smad4. 
Smad4 may regulate terminal differentiation of TEFF cells by IL12 signaling and T-bet expression 
To further understand how Smad4 and TGFb influence the phenotype and proliferative capacity 
of activated CTLs, we investigated whether the OTI-TKO and OTI-SKO cells were responsive to 
cytokine stimulation. Our RNA-Seq data indicated that the β2 subunit of the IL-12 receptor 
(IL12rb2) was downregulated more than 2 fold in EE cells from OTI-SKO mice, as compared to 
OTI-WT cells (Figure 4-3B). IL-12 is a  pro-inflammatory cytokine which promotes terminal 
differentiation of TEFF cells by upregulating T-bet (29). A gradient of T-bet is induced by TCR 
signaling and amplified by IL-12 to promote the formation of KLRG1+ TEFF cells, while low T-bet 
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expression leads to development of memory precursors (28). One mechanism by which IL-12 
regulates T-bet expression is via mTOR complex 1 (mTORC1) signaling. Studies have shown 
that IL-12 uses both PI3K/Akt pathway and STAT4 phosphorylation to enhance mTORC1 
activity during TCR stimulation with costimulatory signals. mTORC1 and mTORC2-dependent 
phosphorylation of Akt further leads to inactivation of the transcription factor Foxo1 which 
suppresses T-bet (158;159).  
We used phospho-flow analysis to determine whether TGFβRII or Smad4 regulates the CD8 T 
cell response by altering IL-12 signaling. We isolated CTLs from the spleens 6dpi and found that 
the STAT4 was phosphorylated at slightly higher levels in OTI-TKO cells than WT CTLs during 
IL-12 stimulation in vitro (Figure 4-10A). Although there was no difference in T-bet expression 
before the peak of the CTL response, the OTI-TKO cells expressed T-bet at slightly higher 
levels than OTI-WT cells during the memory phase of infection (Figure 4-11A, Figure 4-11B).  
We also isolated OTI-SKO cells from the spleens 6dpi, for use in similar experiments. In 
contrast to the OTI-TKO cells, we found that Stat4 was phosphorylated at significantly lower 
levels in OTI-SKO cells than control cells after in vitro stimulation with IL-12 (Figure 4-10A). We 
also used phosphorylation of S6 to assess signaling via the PI3K/Akt/mTORC1 pathway (160). 
Ex-vivo analysis showed reduced Phosphorylation of S6 in OTI-SKO TEFF cells, as compared to 
WT cells (Figure 4-10C), which is consistent with reduced mTORC1 activity. These results 
support our hypothesis that IL-12 signaling is compromised in the absence of Smad4. Since we 
found no difference in phosphorylation of STAT5 after IL-2 stimulation in vitro (Figure 4-10B), 
the defects appear to be specific for the IL-12 signaling pathway. Although IL-12 is known to 
promote terminal differentiation of TEFF cells by upregulating T-bet (29), our experiments with 
OTI-SKO cells revealed only minor differences in T-bet expression during IAV infection (Figure 
4-11). Based on this result, we postulate that Smad4 may control additional regulatory 
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molecules involved in terminal differentiation of TEFF cells, which leads to reduced numbers of 
KLRG1+ TEFF cells in absence of Smad4. 
Smad4 and TGFβ cooperate to regulate TRM and TCM development 
Previous studies have shown that downregulation of T-bet and Eomes is essential for the 
development of CD103+ TRM cells in the lungs and skin (146;161). These T-box transcription 
factors can suppress expression of the TGFβ receptor and downstream signaling pathways 
(146). Conversely, signals from the TGFβ receptor can reduce expression of both transcription 
factors in activated CTLs (146). In our studies, OTI-WT cells only upregulated CD103 in the 
lungs, where Eomes was expressed at low levels (Figure 4-12). The OTI-TKO cells expressed 
Eomes at higher levels than OTI-WT cells at all time points analyzed (Figure 4-12A, Figure 4-
12B), and also expressed T-bet at slightly higher levels than the control cells 15dpi (Figure 4-11), 
which may explain the deficient development of CD103+ TRM cells in the absence of TGFβ 
receptor (Figure 4-12C). In contrast, OTI-SKO cells expressed Eomes at low levels at all time 
points analyzed (Figure 4-12A, Figure 4-12B), and T-bet expression was also moderately 
reduced in OTI-SKO cells (Figure 4-11). Reduced levels of these T-box transcription factor may 
lead to widespread expression of CD103 on OTI-SKO cells (Figure 4-12C), and there was no 
difference in Eomes expression between the CD103+ and CD103- OTI-SKO cell subsets 
(Figure 4-12C).  
Previous studies have also shown that Eomes promotes the formation of CD62L+ TCM cells 
(147). Consistent with this concept, some OTI-WT cells expressed CD62L in local lymph nodes 
which corresponded with high Eomes expression (Figure 4-12D). We found that a higher 
proportion of the OTI-TKO cells re-expressed CD62L in the lymphoid organs 15dpi as compared 
to WT cells and corresponded with high Eomes expression (Figure 4-12D). In contrast, low 
Eomes expression in the OTI-SKO cells was associated with decreased numbers of CD62L+ 
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TCM cells in the resting lymph nodes (Figure 4-12D). Based on these data we postulate that 
Smad4 and TGFβ may counter-regulate memory formation by adjusting the ratio of T-bet and 
Eomes. 
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Discussion 
The data in this chapter explore the mechanisms by which Smad4 regulates effector and 
memory CD8 T cell differentiation. Our RNA-Seq data showed that several phenotypic markers 
were transcriptionally altered in undifferentiated EE cells lacking Smad4, including CD103, 
CD127 and CD62L. In addition, GSEA suggests that the transcription signature for TRM cells 
was enriched in SKO CTLs before 6dpi. We postulate that Smad4 installs a unique 
transcriptional profile in TEFF cells during an early phase of the CTL response. 
The literature shows that rapidly proliferating TEFF cells are fueled by enhanced glycolysis (116). 
We were not able to detect any significant difference in glycolysis between EE cells from OTI-
WT and OTI-TKO mice at any time point during IAV infection. However, memory precursor cells 
lacking the TGFβ receptor showed signs of prolonged glycolysis 8dpi, while the WT cells 
reverted to OXPHOS. The EE cells from the OTI-TKO mice also had limited spare respiratory 
capacity, which is crucial for the development and persistence of memory CD8 T cells (123). It 
is possible that inefficient induction or maintenance of SRC favors terminal differentiation of TEFF 
cells, over memory precursor formation by OTI-TKO cells. Based on these data we postulate 
that TGFβ inhibits terminal differentiation of TEFF cells by curtailing glycolysis and promoting 
SRC in developing memory CD8 T cells.   
Our RNA-Seq data showed low expression of c-Myc and its downstream target AP4 in the SKO 
CTLs analyzed 6dpi. Despite the fact that c-Myc and AP4 play crucial roles in initiating and 
sustaining the glycolytic activity of TEFF cells, the OTI-SKO cells did not show any deficiency in 
the Glycolytic Stress Test. The metabolic state of TEFF cells is regulated by several factors (114), 
that could compensate for low c-Myc and AP4 expression. Consistently, we did not find 
significant differences in the transcription levels of enzymes that are important for glycolysis. 
The OTI-SKO CTLs were also capable of proliferating at similar a rate to OTI-WT cells during 
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IAV infection. We found some evidence that Smad4 deletion-promotes mitochondria biogenesis, 
since that OTI-SKO TEFF cells consumed more oxygen under both basal and stress conditions 
during tests performed 3.5dpi. Studies have shown that CD8 T cells undergo a metabolic switch 
from OXPHOS to glycolysis upon activation, while cells the survive the contraction of the TEFF 
response switch back to OXPHOS during memory development (115;122). There was no 
difference in OXPHOS during the expansion phase of infection, but the OTI-SKO cells displayed 
higher maximal OCR at the peak of the response than WT cells. Overall these data suggest that 
Smad4 may regulate the balance between OXPHOS and glycolysis by favoring mitochondria 
respiration. 
Although the TGFβ receptor and Smad4 mutations altered OXPHOS, there were no differences 
in the types of fuels that could be utilized for mitochondrial respiration. The OTI-SKO, OTI-TKO 
and OTI-WT cells had a similar capacity to generate energy from glucose, fatty acids and amino 
acids during deprivation of individual nutrients. Consistently, our RNA-Seq data did not indicate 
substantial changes in the pathways that are involved in utilization of these substrates. It is 
possible that the process of harvesting and sorting of TEFF cells altered their metabolic state, or 
that the in vitro assays did not accurately mimic the nutrient environment in vivo. 
The IL-12 receptor is composed of two subunits (β1 and β2). The IL-12Rβ2 subunit is part of a 
high affinity receptor which is transcriptionally regulated, while the low affinity IL-12Rβ1 receptor 
is constitutively expressed (162). Since the RNA-sequencing data indicated reduced 
transcription of the Il12rb2 gene in OTI-SKO cells 6dpi, we postulate that low expression of the 
high affinity IL-12 receptor contributed low numbers of KLRG1+ TEFF cells during infection. 
Consistently, phospho-flow analysis showed decreased STAT4 phosphorylation and mTORC1 
signaling in OTI-SKO cells during IL-12 stimulation. Since IAV infection does not induce large 
numbers of KLRG1+ CTLs, we performed similar experiments with mice that were infected with 
recombinant Listeria Monocytogene expressing the OVA epitope (LM-OVA),  which is a 
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pathogen that induces high amounts of IL-12 and KLRG1+ TEFF cells during infection (163). The 
OTI-SKO cells did not produce very many KLRG1+ TEFF cells during LM-OVA infection (data not 
shown). When the CTLs were examined directly ex vivo, the level of phosphorylated S6 was 
significantly decreased early after activation (d2.5) and during the expansion phase of infection 
(d5). Furthermore the OTI-SKO cells expressed T-bet at reduced levels during activation (d2.5) 
and the memory phase of infection (d15) (data not shown). These data support the idea that 
Smad4 supports terminal differentiation of TEFF cells by enhancing or maintaining IL-12 signaling 
and T-bet expression. Further experiments will confirm that Il12rb2 is expressed at low levels in 
SKO CTLs by qPCR and flow cytometry. However it remains unclear how Smad4 regulates IL-
12 receptor expression.  
Studies have shown that TGFβ can reduce T-bet expression in pulmonary and skin TRM cells 
(146;161). We found slightly enhanced expression of T-bet in the absence of TGFβRII during 
the memory phase of infection with IAV. Our data indicate that TGFβ and Smad4 are both 
involved in regulating the balance between TRM and TCM cells, possibly by regulating Eomes and 
T-bet expression. We postulate that high expressions of Eomes and T-bet render the TKO CTLs 
incapable of acquiring a CD103+ phenotype, but promote the formation of CD62L+ TCM cells. In 
contrast, low expression of T-bet and Eomes in Smad4 deficient cells may be responsible for 
widespread CD103 expression in the spleens and lymphoid tissues after IAV infection.  
Previous studies indicate that T-bet and Eomes are reciprocally regulated in TEFF cells (158). 
Upon CD8 T cell activation, Eomes expression is induced via a Runx3-dependent process (164), 
and expression can be amplified by IL-2 (165). Since Eomes is a target gene of Foxo1, 
expression levels can be suppressed by IL-12 signaling via the PI3K/Akt/mTOR pathway (54). 
In our studies the TKO and SKO cells responded to IL-2 stimulation in vitro and phosphorylated 
STAT5 normally. Still, it remains to be explored whether another signal is involved in regulating 
Eomes expression in TKO and SKO CTLs. Also, T-bet and Eomes cooperate to regulate 
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effector functions by inducing the expression of IFNγ, granzyme B and perforin, and CD8 T cells 
lacking both T-bet and Eomes differentiated into IL17-producing CTLs (164). While IFNγ and 
TNF production in response to peptide stimulation in vitro was unaltered by TGFβRII or Smad4 
deletion, further study is needed to determine the production of other effector molecules and 
cytokines, and the effector function of these CTLs by killing assay. 
In summary, this chapter shows that Smad4 establishes a unique transcription profile in TEFF 
cells at early stage of the CD8 T cell response. While Smad4 and TGFβ may be involved in the 
balance between OXPHOS and glycolysis, deletion of these genes did not affect the usage of 
different nutrient substrates. Importantly, our data indicate that Smad4 acts upstream of two 
master transcription factors, T-bet and Eomes, to regulate effector and memory differentiation.  
 
90 
 
Figure 4-1 
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Figure 4-1. Metabolic pathways in CD8 T cells 
Naïve CD8 T cells use fatty acid oxidation (FAO), or oxidative phosphorylation (OXPHOS) of 
glucose-derived pyruvate in mitochondria, to generate energy. During this process acetyl CoA is 
oxidized in the tricarboxylic acid (TCA) cycle to generate NADPH, which fuels ATP production 
via the electron transport chain (ETC). Upon activation, CD8 T cells undergo a metabolic switch 
characterized by enhanced glycolysis, during which glucose is fermented into lactate despite of 
the presence of sufficient oxygen. Activated T cells also upregulate OXPHOS of glutamine in 
mitochondria, and downregulate FAO in favor of fatty acid synthesis (FAS). These metabolic 
changes are essential for biomass synthesis, which supports cell growth, extensive proliferation 
and effector functions of TEFF cells. After the peak of the response, development of memory 
CD8 T cells involves conversion of cellular metabolism back to a catabolic state that primarily 
relies on FAO and OXPHOS. We have examined the role of individual pathways in CD8 T cell 
metabolism using the pharmaceutical inhibitors shown in blue. 
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Figure 4-2. Sorting strategy for RNA-Sequencing 
C57BL/6 mice received mixed populations of congenically marked naïve OTI-WT and OTI SKO 
cells 48hrs before X31-OVA infection. Transferred cells were recovered from pools of three 
spleens 6dpi (total 9 mice) and divided into subsets using KLRG1, CD127, CD103 and 
CD44 expression.  
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Figure 4-3. Altered gene expression in Smad4-deficient CTLs 
RNA was extracted from KLRG1lo CD127lo CD103lo CD44hi OTI-WT and OTI-SKO cells for RNA-
Sequencing. The heatmap shows changes in gene expression greater than two fold (Log2 fold 
change >1 or <-1, p<0.05, false discovery rate<0.05). Comparative values are calculated as 
fragments per kilobase of transcript per million mapped reads (FPKM), standardized by row Z-
score (z=(x-μ)/σ) and plotted on a color scale. Red indicates high expression and blue indicates 
low expression in OTI-SKO cells relative to OTI-WT cells.  
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Figure 4-4. Smad4-deficiency changes the transcriptional profile of TEFF cells during the 
early phase of the CTL response. 
(A) Ingenuity Pathway Analysis was used to assess the function roles of genes with 
transcriptional changes greater than two fold (Log2 fold change >1 or <-1, p<0.05, false 
discovery rate<0.05). The list shows the top 5 molecular and cellular functions with significant 
transcriptional changes between the OTI-WT and OTI-SKO cells. 
(B) Differentially expressed genes were grouped based on their functions. Expression values 
are plotted by Z-scores with red indicating high expression and blue indicating low expression in 
the OTI-SKO cells.  
(C) Gene Set Enrichment Analysis (GSEA) was used to compare genes that were differentially 
expressed in OTI-WT and OTI-SKO cells with a reference set from the literature. The reference 
set is composed of genes identified by comparing TRM cells in IAV infected lungs with circulating 
TCM cells after HSV infection 30dpi (Log2 fold change >2 or <-2).  
(D) Genes with significantly differential expression in RNA-Seq were compared with a previously 
defined core signature of genes shared by skin, gut and lung TRM cells. Genes that exhibited a 
similar regulation pattern in our RNA-Seq and the published TRM signature are listed. 
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Figure 4-5. Smad4 regulates the transcription of genes involved in cellular metabolism 
(A) Gene Set Enrichment Analysis was used to compare the transcriptional profile of OTI-SKO 
cells with a transcriptional signature of myc-deficient TEFF cells from the literature. The genes in 
the reference set were upregulated more than 4-fold in ERT-Cre mycflox/flox CD8 T cells 3 days 
after in vitro activation. c-Myc was deleted by tamoxifen on day 1 after activation. 
 (B) The heat map shows genes with differential expression between OTI-SKO and OTI-WT 
cells that are involved in cellular metabolism, with red indicating high expression and blue 
indicating low expression in OTI-SKO cells. 
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Figure 4-6. TGFβ may decrease glycolysis in memory precursors 
C57BL/6 mice received mixed populations of congenically marked naïve OTI-WT and OTI-TKO 
cells, or OTI-WT and OTI-SKO cells 48hrs before X31-OVA infection. Early effector cells (EECs) 
and memory precursor effector cells (MPECs) were isolated from lymphoid tissues at indicated 
time points based on KLRG1 and CD127 expression. The cells were plated at 2x105 cells per 
well (3-4 wells/group) for analysis using the Glycolysis Stress Test and a XF-96 Extracellular 
Flux Analyzer. 
(A) Extracellular acidification rates (ECAR) for early effector cells from OTI-WT, OTI-TKO and 
OTI-SKO mice  during treatment with Glucose (Glc, 10mM); Oligomycin (Oligo, 4μM); 2-Deoxy- 
D–glucose (2-DG, 50mM). 
(B) Extracellular acidification rates (ECAR) for MPEC cells from OTI-WT (grey), OTI-TKO (white) 
and OTI-SKO (hatched) mice 8dpi. Bar graphs show basal glycolysis, maximum glycolytic 
capacity, and glycolytic. Means ± SD.  *p <0.05, **p < 0.01. 
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Figure 4-7. Smad4 may regulate mitochondrial respiration in activated CTLs 
C57BL/6 mice received mixed populations of congenically marked naïve OTI-WT and OTI-TKO 
cells, or OTI-WT and OTI-SKO cells 48hrs before X31-OVA infection. Early effector cells (EECs) 
and memory precursor effector cells (MPECs) were isolated from lymphoid tissues at indicated 
time points based on KLRG1 and CD127 expression. The cells were plated at 2x105 cells per 
well (3-4 wells/group) for analysis using the Mito Stress Test and a XF-96 Extracellular Flux 
Analyzer  
 (A) Oxygen consumption by early effector cells from OTI-WT, OTI-TKO and OTI-SKO mice. 
during treatment Oligomycin (Oligo, 4μM), Carbonyl cyanide-4 (trifluoromethoxy) 
phenylhydrazone (FCCP, 0.5μM), and Retenone/Antimycin (R/A, 0.5μM). 
(B) Oxygen consumption by MPEC cells from OTI-WT (grey), OTI-TKO (white) and OTI-SKO 
(hatched) mice 8dpi.  
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Figure 4-8. TGFβ increases spare respiratory capacity while Smad4 may suppress 
OXPHOS 
Basal oxygen consumption rate (OCR), maximum OCR, and spare respiratory capacity (SRC) 
for OTI-WT (grey shading), OTI-TKO (white), OTI-SKO (hatched) cells during Mito Stress Test. 
Values were calculated using the data shown in Figure 4-6. Means ± SD.  *p <0.05, **p < 0.01, 
***p<0.005. 
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Figure 4-9. TGFβ or Smad4 deletion does not alter mitochondrial fuel usage 
C57BL/6 mice received mixed populations of congenically marked naïve OTI-WT and OTI-TKO 
cells, or OTI-WT and OTI-SKO cells 48hrs before X31-OVA infection. Early effector cells (EECs) 
and memory precursor effector cells (MPECs) were isolated from lymphoid tissues at the 
indicated time points based on KLRG1 and CD127 expression. The cells were plated at 2x105 
cells per well (3-4 wells/group) for analysis using the Mito Stress Kit and a XF-96 Extracellular 
Flux Analyzer. 
 (A) Oxygen consumption rate by EECs and MPEC during treatment with Oligomycin (4μM), 
FCCP (0.5μM), Etomoxir (200mM) and Retenone/Antimycin (0.5μM). OXPHOS from fatty acid 
oxidation (FAO) was determined by the percentage of maximal OCR decreased in response to 
Etomoxir. *p <0.05. 
(B) OXPHOS by EECs from OTI-TKO (left panel) and OTI-SKO (right panel) mice. Cells were 
analyzed 6dpi in media (grey color) or inhibitors (black color). 200μM Etomoxir (inhibitor of fatty 
acid oxidation), 50μM BPTES (inhibitor of glutaminolysis), and 50μM UK5099 (inhibitor of 
glucose-derived pyruvate transport) were used before the injection of Oligomycin. 
(C) Bar graphs show the ratios for basal OCR versus ECAR by EECs from OTI-WT (grey 
shading), OTI-TKO (white), OTI-SKO (hatched) mice. Cells were analyzed 6dpi in the presence 
(+) or absence (-) of glucose (Glc, 25mM) or glutamine (Gln, 2mM). Means ± SD. **p < 0.01. 
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Figure 4-10. Smad4 deletion led to reduced IL-12 signaling 
Congenically marked cells from OTI-WT and OTI-TKO cells, or OTI-WT and OTI-SKO mice 
were sorted for low CD44 expression and transferred into C57BL/6 mice before X31-OVA 
infection. Representative graphs were shown with 3-4 mice/group. 
(A-B) Splenocytes were harvested 6dpi and rested in cell culture media for 2-3 hours. The cells 
were then stimulated with (A) 2ng/ml IL-12 for 1 hour or (B) 5ng/ml IL-2 for 30 minutes, or left 
unstimulated as control. Phosphorylation of S6, STAT4 and STAT5 were determined by 
phospho-flow on gated OTI-WT (grey shading), OTI-TKO or OTI-SKO cells (solid line). 
(C) Phosphorylation of S6 in gated OTI-WT (grey dashed line), OTI-TKO or OTI-SKO (solid line) 
and endogenous cells (grey shading) were determined ex vivo 6 dpi.  
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Figure 4-11. Smad4 promotes T-bet expression in TEFF cells 
Congenically marked OTI-WT and OTI-TKO cells, or OTI-WT and OTI-SKO cells were sorted 
for low CD44 expression and transferred into C57BL/6 mice before X31-OVA infection. Bar 
graphs show means 3-4 mice/group ± SD. *p<0.05, **p < 0.01, ***p<0.005. Two independent 
experiments yielded similar results. 
(A) T-bet expression in OTI-WT (grey dashed line), OTI-TKO or OTI-SKO (solid line) and 
endogenous cells (grey shading) in spleens and lungs. 
(B) Mean fluorescence intensity for T-bet staining in OTI-WT (grey shading), OTI-TKO (white), 
and OTI-SKO (hatched) cells. 
(C) Mean fluorescence intensity of T-bet staining in KLRG1loCD127lo early effector cell (EEC) 
subsets of OTI-WT (grey shading) and OTI-SKO cells (hatched). 
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Figure 4-12. TGFβ and Smad4 reciprocally balance TRM and TCM cell development by 
regulating the level of Eomes 
Congenically marked OTI-WT and OTI-TKO cells, or OTI-WT and OTI-SKO cells were sorted 
for low CD44 expression and transferred into C57BL/6 mice before X31-OVA infection. Two 
independent experiments with 3-4 mice/group yielded similar results.  
(A) Eomes expression in OTI-WT (grey dashed line), OTI-TKO or OTI-SKO (solid line) and 
endogenous cells (grey shading) in spleens and lungs at indicated time points after infection. 
(B) Mean fluorescence intensity for Eomes staining in OTI-WT (grey shading), OTI-TKO (white), 
and OTI-SKO (hatched) cell populations. Bar graphs show means ± SD. *p<0.05, **p < 0.01, 
***p<0.005. 
(C) Contour plots show Eomes and CD103 expression on OTI-WT, OTI-TKO and OTI-SKO cells 
in the inguinal lymph nodes 15dpi.  
(D) Contour plots show Eomes and CD62L expression by OTI-WT (grey shading), OTI-TKO 
(solid line) and OTI-SKO (grey dashed line) cells in inguinal lymph nodes 15dpi. 
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gene id 
WT FPKM 
avg 
SKO FPKM 
avg 
logFC SKO vs 
WT P values FDR values 
Apol9b 0.473957 13.9909 4.88359 0.00005 0.00106695 
Itgae 0.559934 10.1293 4.17714 0.00005 0.00106695 
Xlr3b 0.169004 2.5016 3.88772 0.00005 0.00106695 
Ldlrad4 0.857605 12.6805 3.88616 0.00005 0.00106695 
Lrig1 0.129343 1.25309 3.27621 0.00105 0.0132538 
Ccl1 0.425493 3.80449 3.16049 0.0026 0.0266737 
Osgin1 0.434457 3.23384 2.89596 0.00005 0.00106695 
Ntrk3 0.161671 1.19818 2.88971 0.00005 0.00106695 
Snrpn 0.103321 0.710952 2.78262 0.0014 0.0166164 
Pmepa1 0.415701 2.84695 2.7758 0.00005 0.00106695 
Smoc1 0.15181 1.0007 2.72067 0.00005 0.00106695 
Clec12a 0.800612 5.25632 2.71488 0.00005 0.00106695 
Chit1 0.139254 0.842951 2.59773 0.0006 0.00844667 
Stra6 0.285184 1.53616 2.42937 0.00005 0.00106695 
B4galnt4 0.294419 1.42384 2.27384 0.00005 0.00106695 
Pde9a 0.266168 1.26349 2.24701 0.00005 0.00106695 
Ms4a1 0.440085 1.94388 2.14309 0.00005 0.00106695 
Ly6d 1.27098 5.57013 2.13177 0.00005 0.00106695 
Ifitm2 73.2209 315.195 2.10592 0.00005 0.00106695 
Cd79a 0.94739 4.00567 2.08001 0.00005 0.00106695 
Trim16 0.529912 2.22827 2.0721 0.00005 0.00106695 
Cabp4 0.167867 0.671713 2.00053 0.00355 0.0338821 
Clec4a2 0.150902 0.590796 1.96905 0.00025 0.00420232 
Skil 4.27655 16.6768 1.96332 0.00005 0.00106695 
Cd19 0.278619 1.08009 1.95478 0.00005 0.00106695 
Cd300e 0.244483 0.922832 1.91633 0.00015 0.0027444 
Wdfy1 2.40211 8.9192 1.89261 0.00005 0.00106695 
Mgst2 13.4696 48.9486 1.86156 0.00005 0.00106695 
Nt5e 4.84586 17.5741 1.85863 0.00005 0.00106695 
Ahr 0.546005 1.91558 1.8108 0.00005 0.00106695 
Slc15a2 0.171012 0.59773 1.8054 0.00005 0.00106695 
Ifitm1 359.535 1239.3 1.78532 0.00005 0.00106695 
Gpr34 0.47902 1.64181 1.77713 0.00005 0.00106695 
Clec4n 1.12165 3.83041 1.77188 0.00005 0.00106695 
Xcl1 56.5929 187.945 1.73161 0.00005 0.00106695 
Ncf4 104.251 338.283 1.69817 0.00005 0.00106695 
Adamdec1 0.1811 0.575544 1.66814 0.0005 0.00728161 
Pparg 0.190734 0.602245 1.65879 0.00165 0.0190483 
Aif1 1.52525 4.71307 1.62762 0.00005 0.00106695 
Smpd5 2.91887 8.98112 1.62148 0.00005 0.00106695 
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Nostrin 0.225849 0.694589 1.6208 0.00185 0.0207659 
Hpgd 0.42501 1.27747 1.58772 0.00005 0.00106695 
Isg20 21.0853 62.9184 1.57725 0.00005 0.00106695 
Tsc22d1 2.65905 7.80252 1.55303 0.00005 0.00106695 
Siglece 0.399534 1.1695 1.54949 0.00015 0.0027444 
Ly86 0.944492 2.75718 1.54558 0.00005 0.00106695 
Mgst1 1.32724 3.87377 1.54531 0.00005 0.00106695 
Trf 2.54745 7.2591 1.51074 0.00005 0.00106695 
Zfp1 3.12285 8.88687 1.50881 0.00005 0.00106695 
Ubd 1.48628 4.15867 1.48442 0.00005 0.00106695 
Tnfsf11 0.436528 1.20653 1.46671 0.00005 0.00106695 
Actn2 0.984984 2.71515 1.46286 0.00005 0.00106695 
Wfdc17 3.23602 8.90308 1.46008 0.00005 0.00106695 
Sirpa 0.362194 0.989893 1.45051 0.00005 0.00106695 
Igj 0.275663 0.750231 1.44443 0.00075 0.010136 
Mzb1 0.630755 1.71356 1.44185 0.00245 0.0254178 
Cd74 21.7353 58.5862 1.43052 0.00005 0.00106695 
Gm6682 3.01385 8.06528 1.42012 0.00005 0.00106695 
Ski 2.00806 5.33904 1.41078 0.00005 0.00106695 
Igflr1 16.0449 42.1123 1.39213 0.00005 0.00106695 
Clec7a 0.48677 1.26657 1.37962 0.00005 0.00106695 
Znrf1 0.879341 2.28715 1.37906 0.00005 0.00106695 
Prkcz 0.674504 1.75405 1.37879 0.00005 0.00106695 
Cyp4f18 1.00359 2.60786 1.37769 0.00005 0.00106695 
H2-Aa 10.1775 26.3452 1.37215 0.00005 0.00106695 
Slc40a1 5.01024 12.9556 1.37062 0.00005 0.00106695 
Cd101 0.904812 2.32059 1.3588 0.00005 0.00106695 
Tdgf1 0.247519 0.633122 1.35495 0.00335 0.0325245 
Smurf2 2.21604 5.66591 1.35432 0.00005 0.00106695 
Cd5l 2.32932 5.93757 1.34996 0.00005 0.00106695 
Itga1 0.650255 1.64982 1.34323 0.00005 0.00106695 
Timp2 1.25164 3.17258 1.34183 0.00005 0.00106695 
Spic 3.44003 8.67104 1.33378 0.00005 0.00106695 
Treml4 1.78477 4.49377 1.33219 0.00005 0.00106695 
Ctsh 0.717442 1.8064 1.33218 0.00005 0.00106695 
AF251705 0.495993 1.24613 1.32906 0.00275 0.0277078 
Fcgr4 1.21145 3.01882 1.31725 0.00005 0.00106695 
Hba-a1,Hba-a2 1.79225 4.44333 1.30987 0.0056 0.0483077 
Clec4a1 0.492829 1.21622 1.30325 0.00045 0.00673737 
Alox15 0.241831 0.595398 1.29985 0.00175 0.0199303 
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Alox5ap 1.86947 4.55591 1.28511 0.00005 0.00106695 
Emr4 0.290241 0.703602 1.27751 0.00005 0.00106695 
Pilrb2 0.349515 0.846674 1.27645 0.00055 0.00790752 
Cd302 0.660607 1.59103 1.26809 0.0005 0.00728161 
Adamts6 0.304442 0.73204 1.26576 0.00005 0.00106695 
Gpr25 0.738372 1.7549 1.24897 0.00005 0.00106695 
A930001A20Rik 1.08039 2.56676 1.2484 0.00005 0.00106695 
Vcam1 3.38238 8.00392 1.24267 0.00005 0.00106695 
Gngt2 28.0047 66.1468 1.24 0.00005 0.00106695 
Ccr8 1.11522 2.62516 1.23508 0.00025 0.00420232 
Beta-s 2.47094 5.79766 1.23041 0.0003 0.00481139 
Cpd 0.669247 1.54902 1.21075 0.00005 0.00106695 
Cd14 2.0551 4.71151 1.19698 0.00005 0.00106695 
H2-Ab1 4.91075 11.2582 1.19696 0.00005 0.00106695 
Csf3r 0.396414 0.90815 1.19592 0.00005 0.00106695 
Hebp1 1.00834 2.30729 1.19422 0.0005 0.00728161 
Car2 49.7481 113.292 1.18733 0.00005 0.00106695 
Gpr56 0.860425 1.94781 1.17873 0.00005 0.00106695 
Plaur 1.83661 4.14319 1.1737 0.00005 0.00106695 
Ifitm3 61.9976 138.329 1.15782 0.00005 0.00106695 
Il7r 6.82418 15.1439 1.15001 0.00005 0.00106695 
Cfb 0.432428 0.958073 1.14767 0.00035 0.00544946 
Nr1h3 0.834216 1.84696 1.14666 0.0002 0.00347123 
Card6 0.434881 0.961298 1.14436 0.00005 0.00106695 
Zfyve28 0.355081 0.78432 1.1433 0.00005 0.00106695 
Trp53inp1 2.24681 4.95092 1.13982 0.00005 0.00106695 
Apol7e 2.78206 6.10043 1.13276 0.00005 0.00106695 
Cyp4f16 0.456374 0.99817 1.12907 0.00065 0.00903759 
Lgals7 4.89169 10.6196 1.11832 0.00005 0.00106695 
H6pd 1.80681 3.92196 1.11813 0.00005 0.00106695 
Tgm2 0.451958 0.977916 1.11352 0.00025 0.00420232 
2410066E13Rik 0.609879 1.31876 1.11259 0.0011 0.013782 
Clec4a3 0.835719 1.79818 1.10545 0.00045 0.00673737 
Tgfb3 0.283352 0.607118 1.09938 0.00115 0.0142673 
Fxyd4 3.12148 6.68394 1.09847 0.00025 0.00420232 
Abi3 3.97913 8.48765 1.09291 0.00005 0.00106695 
Hk3 0.444541 0.947071 1.09115 0.00055 0.00790752 
Treml2 0.500225 1.06124 1.08511 0.00005 0.00106695 
Gpr68 16.6537 35.2195 1.08053 0.00005 0.00106695 
Exoc3l 0.923014 1.93958 1.07132 0.00005 0.00106695 
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Herc3 3.60473 7.5183 1.06052 0.00005 0.00106695 
1110032F04Rik 0.579364 1.20566 1.05728 0.00055 0.00790752 
Tyrobp 12.0953 25.1601 1.05669 0.00005 0.00106695 
Fpr1 0.853556 1.77127 1.05323 0.001 0.0127818 
Slpi 11.1663 23.1621 1.05262 0.00005 0.00106695 
Tubb6 3.56027 7.3718 1.05003 0.00005 0.00106695 
Coro2a 4.82731 9.98667 1.04878 0.00005 0.00106695 
Pla2g7 1.54176 3.18522 1.04681 0.00005 0.00106695 
Nucb2 1.07649 2.22055 1.04458 0.00005 0.00106695 
Aldh3b1 0.406258 0.833482 1.03675 0.00475 0.0430644 
Ccr1 0.368808 0.754128 1.03194 0.00095 0.0122509 
Bank1 0.301958 0.617186 1.03136 0.00135 0.0161745 
Wdpcp 0.62804 1.28272 1.03028 0.0003 0.00481139 
Actg2 3.88243 7.91998 1.02854 0.00005 0.00106695 
Hck 0.372092 0.756215 1.02314 0.0052 0.0459923 
Zfp286 0.480721 0.967483 1.00904 0.0004 0.00611523 
Ndrg4 0.503973 1.01301 1.00723 0.0003 0.00481139 
Fcer1g 13.6225 27.3045 1.00315 0.00005 0.00106695 
Thnsl2 0.593658 1.18892 1.00194 0.0018 0.0203625 
Ppan 16.2166 8.05833 -1.00892 0.00005 0.00106695 
Fcgr2b 1.55503 0.769867 -1.01426 0.00085 0.0112182 
Mon1a 4.36323 2.14101 -1.0271 0.00005 0.00106695 
Ndufaf6 3.63118 1.77551 -1.0322 0.00025 0.00420232 
Pgls 54.3735 26.3605 -1.04453 0.00005 0.00106695 
Tfap4 1.89303 0.917472 -1.04496 0.0001 0.00194923 
Klre1 2.38785 1.157 -1.04532 0.00135 0.0161745 
Ncln 20.7909 10.0634 -1.04684 0.00005 0.00106695 
Cass4 0.834876 0.403332 -1.04959 0.0003 0.00481139 
Vcl 2.12142 1.02402 -1.05078 0.00005 0.00106695 
Egfl7 11.146 5.37934 -1.05102 0.00005 0.00106695 
Amacr 0.926152 0.446442 -1.05278 0.0006 0.00844667 
Prpsap1 22.3375 10.6551 -1.06792 0.00005 0.00106695 
Ndrg1 7.61007 3.61925 -1.07222 0.00005 0.00106695 
BC035044 14.9724 7.08461 -1.07954 0.0002 0.00347123 
Cd40lg 4.38038 2.0546 -1.0922 0.00005 0.00106695 
Gas7 1.42671 0.664431 -1.1025 0.00005 0.00106695 
Snx9 1.02742 0.478472 -1.10252 0.0013 0.0156867 
Dusp4 4.11041 1.90117 -1.1124 0.00005 0.00106695 
Il12rb2 7.46018 3.42689 -1.12231 0.00005 0.00106695 
Fam73b 1.7871 0.818919 -1.12582 0.00005 0.00106695 
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Bco2 0.853014 0.388532 -1.13454 0.00195 0.0213909 
Rbm47 1.70923 0.776711 -1.1379 0.00005 0.00106695 
Fam160a2 0.579563 0.261699 -1.14706 0.00005 0.00106695 
Med25 2.47916 1.11462 -1.15331 0.00005 0.00106695 
Crybb1 3.02753 1.34356 -1.17209 0.0007 0.00957517 
Thop1 5.10911 2.26659 -1.17255 0.00005 0.00106695 
Wdr95 5.74354 2.50267 -1.19848 0.00005 0.00106695 
Myc 39.7952 17.0124 -1.22601 0.00005 0.00106695 
Ehd2 0.850203 0.36109 -1.23545 0.00015 0.0027444 
Irak1bp1 0.627635 0.264979 -1.24405 0.00345 0.0333357 
Serpine2 1.15618 0.486288 -1.24948 0.00025 0.00420232 
Map1s 4.23466 1.76697 -1.26097 0.00005 0.00106695 
Sell 35.8891 14.9705 -1.26142 0.00005 0.00106695 
Smad4 4.68181 1.9306 -1.27801 0.00005 0.00106695 
Ydjc 4.37975 1.78581 -1.29427 0.00005 0.00106695 
Trim46 1.05721 0.413773 -1.35335 0.00005 0.00106695 
Tfeb 2.46188 0.962091 -1.35551 0.00005 0.00106695 
Tnfrsf25 0.889051 0.346203 -1.36065 0.0023 0.0243349 
Cblc 0.746897 0.284538 -1.39229 0.00275 0.0277078 
Ccl5 2161.53 822.098 -1.39467 0.00005 0.00106695 
Gimap7 133.178 50.3793 -1.40245 0.00005 0.00106695 
Lamb3 1.53786 0.576776 -1.41484 0.00005 0.00106695 
Hmga1 162.24 59.9278 -1.43683 0.00005 0.00106695 
Hist1h4m 5.83564 2.15347 -1.43823 0.0024 0.0250529 
Ndfip1 67.6603 24.967 -1.43829 0.00005 0.00106695 
Hpdl 1.96099 0.696275 -1.49386 0.00005 0.00106695 
Chchd10 16.1001 5.71545 -1.49413 0.00005 0.00106695 
H2-Q10 37.4232 13.2812 -1.49455 0.00005 0.00106695 
Serpinb9b 6.84584 2.2889 -1.58058 0.00005 0.00106695 
Arl4d 3.34451 1.09684 -1.60844 0.00005 0.00106695 
Eomes 4.89641 1.53838 -1.67031 0.00005 0.00106695 
Ltb4r1 0.807339 0.251671 -1.68163 0.00315 0.0309684 
Prr7 1.10655 0.337841 -1.71165 0.0032 0.0313687 
Parm1 1.57757 0.362293 -2.12247 0.00005 0.00106695 
Ociad2 2.99943 0.501212 -2.5812 0.00005 0.00106695 
Art2b 5.79599 0.907782 -2.67464 0.00005 0.00106695 
Art2a-ps 0.798092 0.12206 -2.70896 0.00515 0.0456696 
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Table 4-1. Genes with significantly differential expression in absence of Smad4 
Congenically marked OTI-WT and OTI-SKO cells were sorted for low CD44 expression and 
transferred into C57BL/6 mice 48hrs before infection with X31-OVA. Transferred cells lacking 
KLRG1, CD127 and CD103 expression were isolated from pools of three spleens 6dpi (total 9 
mice) and used for RNA-Sequencing. All genes with transcriptional changes greater than two 
folds (Log2 fold change >1 or <-1, p<0.05, false discovery rate (FDR) <0.05) are listed. 
 
120 
 
 
 
 
 
 
 
 
 
CHAPTER V 
DISCUSSION AND CONCLUSION 
 
 
 
 
 
 
 
 
121 
 
CD8 T cell differentiation are regulated by TGFβ and Smad4 
In this thesis we have shown that the expression levels of multiple homing receptors are altered 
in the absence of TGFβRII or Smad4, which thus changed the distribution of CTLs in vivo. While 
the kinetics of the CD8 T cell response was unaltered by Smad4 deficiency, as shown by 
normal expansion and contraction, terminal differentiation of KLRG1+ TEFF cells was greatly 
reduced when Smad4 was absent. Upon activation Smad4-deficient (SKO) CTLs expressed 
activation markers similarly to WT cells, yet downregulated CD127 slower than WT cells. They 
also re-expressed CD127 at higher frequency and very few cells acquired a KLRG1+ phenotype. 
When Smad4 was expressed some KLRG1+ WT TEFF cells were found in the lungs at 8dpi by 
confocal microscopy. In normal animals KLRG1+ CTLs have strong lytic activity and facilitate 
viral clearance from the lungs (166). Low numbers of KLRG1+ cells may explain why the SKO 
mice underwent more severe weight loss during primary IAV infection and recovered slower 
than the WT group. To test this hypothesis viral titer can be compared on different time points 
after primary infection. The production of IFNγ and TNF was not affected by Smad4 deletion. 
However, these cytokines, while contributing to IAV pathogenesis, are not required for viral 
clearance (167;168). We will further whether Smad4 regulates effector functions by examining 
other molecules such as granzyme B and perforin. 
Deletion of Smad4 also resulted in widespread expression of CD103 not only in the lungs, but 
also in the spleens and lymph nodes where WT CTLs do not express CD103. This odd 
population of CD103+ SKO CTLs in the circulation did not re-express CD62L, which is required 
for T cell migration across HEVs and entry into resting lymph nodes (169). Consequently, only 
small numbers of SKO cells were found in the resting lymph nodes and expressed CCR7, which 
was sufficient for inefficient migration into the ILN. On the other hand, normal numbers of 
CD103+CD69+ pulmonary TRM cells developed in absence of Smad4. No difference in 
protection between WT and SKO mice was observed during secondary infection, which is 
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consistent with the important role of TRM cells in heterosubtypic immunity (61). Confocal imaging 
will be used to further examine whether Smad4 deficiency alters the localization of antigen-
specific CD8 T cells after re-challenge. 
TGFβRII deficiency also did not significantly alter the kinetics of the CD8 T cell response after 
IAV infection. In contrast to SKO CTLs, TEFF cell differentiation was skewed towards the 
formation of the KLRG1+ subset. This observation is consistent with the literature, as blocking 
TGFβ signaling also led to the accumulation of TEFF cells with a terminally differentiated 
phenotype (KLRG1+) after Listeria Monocytogene infection (86). WT and TKO mice underwent 
similar weight loss during primary infection, which suggest that they can control IAV infection as 
effectively as WT mice. 
Previous studies also show that TGFβ is essential for the generation/maintenance of 
CD103+CD69+ TRM cells in various tissues (63-66). Consistently, while WT antigen-specific 
CD8 T cells upregulated CD103 in the lungs during the memory phase of infection, CD103 and 
CD69 were absence from TGFβRII-deficient (TKO) CTLs in the lungs even at 60dpi, which 
indicates a deficiency in TRM cell development. Confocal microscopy confirmed that OTI-TKO 
cells did not locate in the walls of the airways. The long-lived KLRG1+ TEFF cells were mostly 
found in blood vessels. Development of circulating memory CD8 T cells was not impaired by 
TGFβRII deletion. In fact, increased numbers of CD62L+ TCM cells were observed in the resting 
lymph nodes. A previous study from our lab shows that TRM cells remain poised in the lungs to 
provide frontline defenses during the earliest phase of re-infection. Early viral control resulted in 
less recruitment of circulating memory CD8 T cells and less inflammation in the reinfected lungs 
(61). During secondary infection the TKO mice recovered slightly slower than WT mice. The 
absence of TRM cells may have resulted in delayed viral clearance, and increased migration of 
nascent 2nd TEFF cells to the lungs in these mice. Viral titer will be determined by plaque assay 
or qPCR, and pathology in the lungs will be examined by Hematoxylin and eosin (H&E) staining. 
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The effect of Smad4 on terminal differentiation and memory formation appeared to be 
independent of TGFβRII, as CTLs that were deficient of both Smad4 and TGFβRII (STDKO) 
showed similar phenotypes as SKO cells. The STDKO mice also behaved similarly to SKO mice 
in protection studies, and recovered from primary infection with delayed kinetics. Our model 
suggests that an unknown ligand (we refer to as Smad4 ligand) signals through Smad4 to 
promote formation of KLRG1+ TEFF cells. This pathway, which also suppresses CD103 and is 
required for CD62L expression on TCM cells, may be counter-regulated by TGFβ via a 
mechanism that may involve competition for Smad4. Further study is required to identify the 
Smad4 ligand. A recent study shows that conditional deletion of TGFβRII on memory CD8 T 
cells results in upregulation of KLRG1, which may be driven by basal inflammation from 
commensal microbiota (170). Therefore it is possible that Smad4 ligand can also be induced by 
commensal microbiota, and continuous counter-regulation by TGFβ is required to avoid KLRG1 
expression. For the purpose of effective and safe vaccination against IAV infection, an ideal 
CTL response should elicit low numbers of KLRG1+ TEFF cells, which can be pathogenic, while 
generating sufficient numbers of TRM cells in lungs. Therefore pharmaceutical inhibition of 
Smad4 may serve to facilitate the development of a new IAV vaccine by optimizing and 
sustaining cell-mediated immunity. 
Smad4 may regulate TEFF cell generation via IL-12 signaling 
IL-12 is an important inflammatory cytokine in the CD8 T cell response, which is known to 
promote terminal differentiation of TEFF cells (29). IL-12 signaling enhances mTORC1 activity 
through the PI3K/Akt pathway and STAT4 phosphorylation (158). Early exposure to IL-12 can 
also sustain expression of the expression of high-affinity IL-2 receptor, CD25, and prolong cell 
proliferation during the late phase of the CD8 T cell response, which is associated with terminal 
differentiation of TEFF cells (51).  
124 
 
While no difference in cell proliferation was observed at early time points, the TKO cells showed 
increased BrdU incorporation at and after the peak of the CTL response. It is possible that CTLs 
lacking TGFβRII are more sensitive to low concentrations of costimulatory molecules, or 
cytokines that induce cell proliferation during the late phase of infection. The IL-12 receptor is 
known to be downregulated by TGFβ on CD4 T cells (171). Though IL-12 stimulation in vitro 
resulted in a slightly higher level of phosphorylated STAT4 in OTI-TKO cells at 6dpi, no 
difference was observed in mTORC1 activity, as shown by the phosphorylation level of S6. We 
also did not observe a difference in CD25 expression, or responsiveness to IL-2 stimulation in 
vitro between the OTI-TKO and OTI-WT cells. We will use qPCR to compare the transcription 
levels of IL-12 receptor, as well as other costimulatory molecules and cytokine receptors. 
Responsiveness to other cytokines can also be examined through in vitro stimulation and 
phospho-flow. At early time points, when there was no significant difference in cell survival and 
proliferation, lack of TGFβRII resulted in faster downregulation of CD127 at d3.5, and at 6dpi. At 
this time there were already higher frequencies of KLRG1+ cells and lower frequencies of 
memory precursors among the TKO cell population. So we also need to consider the possibility 
that prolonged proliferation may not be the only mechanism leading to the accumulation of 
KLRG1+ TEFF cells among TKO CTLs.  
Our RNA-Seq showed that the Il12rb2 gene, which encodes the IL-12 receptor β2 chain, was 
downregulated in the OTI-SKO cells. Indeed, IL-12 stimulation in vitro resulted in lower level of 
phosphorylated STAT4 and S6 in OTI-SKO cells at 6dpi. OTI-SKO cells also showed reduced 
S6 phosphorylation directly ex vivo at 6dpi. These results suggest that Smad4 deletion results in 
weaker transduction of IL-12 signaling in vitro and in vivo. Additional qPCR and flow cytometry 
are needed to confirm decreased expression of the IL-12 receptor on SKO CTLs as compared 
to WT cells. Also, it remains unclear how Smad4 regulates IL-12 receptor expression. As il12rb2 
is known to be downregulated by TGFβ on CD4 T cells (171), it is possible that the unknown 
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‘Smad4 ligand‘ may induce Il12rb2 transcription, while TGFβ suppresses transcription by 
competing away Smad4 with phosphorylated Smad2/3. 
Transcription factors are regulated by Smad4 and TGFβ 
IL-12 is known to promote terminal differentiation of TEFF cells by upregulating the transcription 
factor, T-bet (29). Despite of the accumulation of KLRG1+ TEFF cells in absence of TGFβRII, no 
difference in T-bet expression was observed between TKO and WT CTLs during the acute 
phase of CD8 T cell response. We will use qPCR and intracellular flow cytometry to further 
examine the expression levels of other important transcription factors known to promote 
KLRG1+ TEFF cell formation, including Blimp-1, Id2 and Zeb2 (134;135;138;172). 
On the other hand, while OTI-SKO cells showed reduced responsiveness to IL-12 stimulation in 
vitro, we only found a small reduction of T-bet in SKO CTLs after IAV infection. Nevertheless, 
OTI-SKO cells expressed significantly reduced levels of T-bet from 2.5dpi with LM-OVA 
infection. This may reflect a difference in the inflammatory environment during the two types of 
infection. The literature shows that LM infection can generate high concentrations of IL-12 and 
large numbers of KLRG1+ TEFF cells (163), while relatively few KLRG1+ TEFF cells can be found 
during IAV infection. It is possible that IAV infection induces low amounts of IL-12, or the Smad4 
ligand which may be required for IL-12 receptor expression, which leads to relatively low IL-12-
induced T-bet expression in WT cells. It is possible that TCR signaling can compensate for 
reduced IL-12 signaling in SKO CTLs and induce T-bet expression to a similar level as the WT 
cells. Also, in our model high concentrations of TGFβ are activated by the IAV neuraminidase, 
which may reduce IL-12 receptor expression on the WT cells and therefore minimize the 
difference in T-bet expression between WT and SKO CTLs. We could test these possibilities in 
vitro by modulating the concentration of antigen, IL-12 and TGFβ. Nevertheless, considering the 
key role of T-bet in promoting KLRG1+ TEFF cell generation (29), decreased T-bet expression 
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may explain why SKO CTLs preferentially differentiated into memory precursors. To further 
prove this hypothesis, we will transduce OTI-SKO cells with a retrovirus expressing T-bet, and 
examine whether enforced expression of T-bet restores terminal differentiation in absence of 
Smad4. 
Recent studies show that proper development of TRM cells in lungs and skin requires 
downregulation of T-bet and Eomes (146;161). TGFβ signaling, which is enhanced by such 
downregulation, can further suppress the expression of these two transcription factors (146). 
Consistently, we found that while T-bet expression was unaltered in TEFF cells until the peak of 
the response, memory CD8 T cells lacking TGFβRII retained a significantly higher level of T-bet 
than the WT counterpart. Also, a lack of TGFβ signal in these cells resulted in increased 
induction and maintenance of Eomes throughout the CD8 T cell response. As enforced 
expression of these two transcription factors abrogated formation of TRM cells in skin (146), high 
level of T-bet and Eomes maintained by TKO CTLs may lead to their deficiency in TRM cell 
development. This hypothesis can be tested by knocking down Eomes and T-bet in TKO CTLs 
with retroviruses expressing small interfering RNA (siRNA).  
On the other hand, Eomes and T-bet were both expressed at lower levels in SKO CTLs. Though 
WT CTLs in the lungs expressing CD103 had lower Eomes and T-bet expression than the 
CD103- counterparts, both CD103+ and CD103- SKO CTLs expressed low levels of these two 
transcription factors. To answer the question whether Smad4 suppresses CD103 expression via 
these two transcription factors, using retrovirus expressing T-bet or Eomes, we will examine 
whether enforced expression of these two transcription factors can reverse the widespread 
expression of CD103 in lymphoid tissues in absence of Smad4. A recent study showed that T-
bet can directly bind to the regulatory region of the CD103 gene (161). It would be interesting to 
examine whether Eomes also directly regulates CD103 expression. Also, it remained unclear as 
how Smad4 promotes Eomes expression. Eomes expression is known to be amplified by IL-2 
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(165), yet we did not observe difference in phosphorylated STAT5 after IL-2 stimulation in vitro 
in OTI-SKO cells at 6dpi.  
As Eomes deficiency can diminish TCM cell population (147), enhanced Eomes expression in 
the OTI-TKO cells may also explain why higher frequencies of these cells expressed CD62L at 
memory phase in lymphoid organs, and were found at increased numbers than WT cells in 
resting lymph nodes at 30dpi by confocal microscopy. On the other hand, low level of Eomes in 
the SKO CTLs may render these cells unable to develop into CD62L+ TCM cells. Therefore, 
while Eomes did not control the differentiation of KLRG1+ and CD127+ effector subsets (147), 
altered expression of Eomes may be associated with the balance between CD103+ TRM and 
CD62L+ TCM cell development. It would be interesting to examine whether enforced expression 
of Eomes can rescue the impaired development of TCM cells among SKO cell population.  
Metabolic profiles of CTLs are altered by TGFβ and Smad4 
Enhanced glycolysis is generally associated with a higher proliferative capacity and terminal 
differentiation of TEFF cells (116;123). Nevertheless, here we did not observe a significant 
difference in the glycolytic stress test between TKO and WT early effector cells analyzed directly 
ex vivo. Nevertheless, TGFβRII deficiency resulted in decreased spare respiratory capacity 
(SRC), which is a unique property of memory CD8 T cells generated in vitro (123), and 
consistent with the fact that lower frequencies of memory precursors were observed among the 
TKO population. Moreover, the TKO TEFF cells that had acquired a CD127+ memory precursor 
phenotype seemed to be ‘addicted’ to glycolysis and deficient in conversation back to 
mitochondria respiration, as shown by enhanced glycolytic activity and reduced OXPHOS as 
compared to WT CTLs. We still need to consider the possibility that these cells may behave 
differently in vivo and the in vitro environment. Therefore sorted cells can be treated with TGFβ 
before the metabolic tests to determine whether the presence of TGFβ alters glycolysis or 
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OXPHOS activity. Also, previous studies with in vitro activated CD8 T cells showed that SRC is 
a unique feature of IL-15-derived memory CD8 T cells, while IL-2-derived effector CD8 T cells 
are highly glycolytic and do not maintain SRC (123;124).  In our experiments TEFF cells isolated 
from recipient mice at different time points were all metabolically similar to in vitro memory CD8 
T cells in the mito stress test (123;124). One possible explanation is that, compared to in vivo 
generated CTLs, CD8 T cells activated in vitro may receive much stronger signals from anti-
CD3/CD28 antibodies and a high concentration of IL-2 in culture, which can be tested by a 
titration of these stimulations. Also, the concentrations of nutrients were much higher in cell 
culture media than in vivo settings. For example, the concentration of glucose used in these in 
vitro studies were 25 mM, while the level of glucose is around 5mM in lymphoid tissues, and the 
availability of nutrients may be further reduced at the infection site (114). Therefore in vitro 
generated TEFF cells may appear to be more glycolytic than the TEFF cells analyzed ex vivo in 
our study.  
We did not observe any difference in mitochondrial fuel usage between the TKO and WT CTLs. 
In both types of cells, fatty acid oxidation supported OXPHOS at both basal and under stress 
condition. While OCR was not altered by BPTES-mediated glutominolysis inhibition, the influx of 
glucose-derived pyruvate into the TCA cycle was necessary to support maximal OCR and SRC. 
Consistently, recent studies have shown that memory CD8 T cells generated in vitro did not 
import exogenous fatty acids, but actively used extracellular glucose to synthesize lipids which 
fueled FAO through intrinsic lipolysis and maintained OXPHOS and SRC (124).  
On the other hand, RNA-Seq revealed downregulation in transcription of c-Myc and its target 
gene AP4 in SKO early effector cells (EECs). In addition, a recent study suggests that Smad4 
may promote cell proliferation by directly regulating c-Myc expression (148). Despite the key 
roles of c-Myc and AP4 in enhancing and maintaining glycolytic metabolism upon T cell 
activation, no difference in glycolytic activity was observed between SKO and WT EECs at 
129 
 
various time points. On the other hand, SKO EECs showed enhanced basal and maximal OCR 
at 3.5dpi, which may suggest enhanced mitochondria biogenesis in absence of Smad4. To test 
this hypothesis, cells could be stained with mitochondria-specific dyes to compare mitochondria 
mass and membrane potential by flow cytometry and confocal microscopy. The difference in 
OXPHOS was not observed between WT and SKO EECs at 6dpi. The absence of Smad4 also 
did not alter mitochondria fuel usage at this time point. Consistently, RNA-Seq did not reveal 
significant change in the expression levels of key genes involved in OXPHOS, such as carnitine 
palmitoyltransferase 1α (CPT1α) or mitochondrial transcription factor A (TFAM). At 8dpi, 
however, SKO EECs again showed higher OCR under stressed conditions, which may suggest 
faster conversion back to OXPHOS. These data suggests Smad4 deletion may influence the 
balance between OXPHOS and glycolysis at these metabolic switch points. Further studies are 
needed to examine whether the expression level or activity of key enzymes that are involved in 
OXPHOS and glycolysis are altered by the absence of Smad4 at these two time points.  
In conclusion, in this thesis we have demonstrated the distinctive roles of TGFβ and its 
downstream molecule, Smad4, in effector and memory CD8 T cell differentiation after IAV 
infection (Figure 5-1). A novel pathway, which we believe is triggered by an unknown Smad4 
ligand, can promote terminal differentiation and acquisition of the KLRG1+ phenotype. The 
mechanism may involve enhanced IL-12 signaling and T-bet expression, and possibly also 
inhibiting OXPHOS activity. Smad4-mediated generation of the KLRG1+ TEFF cell subset may 
promote viral clearance during primary infection, yet is not required for protection during the 
recall response. Our data suggest that Smad4 acts as a suppressor of CD103 during TRM cell 
development and promotes conversion of TEFF cells to CD62L+ TCM cells, through enhanced 
Eomes and T-bet expression. On the other hand, TGFβ, possibly by preventing Smad4 from 
activating its target genes with phosphorylated Smad2/3, inhibits KLRG1+ TEFF cell in favor of 
memory precursor formation, and may also promote a metabolic switch from glycolysis back to 
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mitochondria respiration. Also, by downregulating Eomes and T-bet TGFβ signal is essential for 
the generation/maintenance of pulmonary TRM cells, which play a key role in heterosubtypic 
immunity. These data provide a better understanding on the signaling pathways governing the 
generation of different subsets of antigen-specific CD8 T cells participating in cell-mediated 
immunity against IAVs, and may facilitate the development of IAV vaccine with long-lasting 
protection.  
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Figure 5-1. Model summarizing the roles of TGFβ and Smad4 in effector and memory CD8 
T cell differentiation  
(1) An unknown receptor uses a novel Smad4-dependent signaling pathway to promote CD8 T 
cell proliferation and TEFF differentiation. (2) The transcriptional targets of this signaling pathway 
include the IL-12 receptor, which can signal through (3) STAT4 or (4) the PI3K/Akt/mTOR 
pathway to promote T-bet expression during terminal differentiation of KLRG1+ TEFF cells. (5) 
Smad4 is a repressor of the Itgae gene (CD103) during development of TRM cells, and promotes 
re-expression of the sell gene (CD62L) on TCM cells by a mechanism that may involve Eomes. 
(6) TGFβ suppresses terminal differentiation of KLRG1+ TEFF cells and (7) promotes re-
expression of CD103 on TRM cells by a mechanism may involve competition within the Smad 
signaling cascade. 
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